CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (English)
- New search for: Holleman, M.S.
- New search for: Al, M.J.
- New search for: Uyl-de Groot, C.A.
- New search for: Holleman, M.S.
- New search for: Al, M.J.
- New search for: Uyl-de Groot, C.A.
In:
Value in health
;
21
, 3
;
S3
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
-
Contributors:
-
Published in:Value in health ; 21, 3 ; S3
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam
-
Publication date:2018-01-01
-
Size:S3
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 610.28
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 610.28 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 21, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 249
-
Affordability of New Technologies: The Next FrontierTowse, Adrian / Mauskopf, Josephine A. et al. | 2018
- 252
-
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and CuresDanzon, Patricia M. et al. | 2018
- 258
-
The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValuePearson, Steven D. et al. | 2018
- 266
-
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsLomas, James / Claxton, Karl / Martin, Stephen / Soares, Marta et al. | 2018
- 276
-
Paying for Cures: Perspectives on Solutions to the "Affordability Issue"Schaffer, Sarah Karlsberg / Messner, Donna / Mestre-Ferrandiz, Jorge / Tambor, Ellen / Towse, Adrian et al. | 2018
- 280
-
Affordability of Health Care: A Global CrisisWatkins, John B. et al. | 2018
- 283
-
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee ArthroplastiesKuznietsova, Victoria / Woodward, Robert S. et al. | 2018
- 295
-
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational StudyRapp, Thomas / Andrieu, Sandrine / Chartier, Florence / Deberdt, Walter / Reed, Catherine / Belger, Mark / Vellas, Bruno et al. | 2018
- 304
-
Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer PatientsZhong, Yue / Valderrama, Adriana / Yao, Jianying / Donga, Prina / Bilir, Pinar / Neumann, Peter J. et al. | 2018
- 310
-
Cost-Effectiveness of Antibiotic Prophylaxis Strategies for Transrectal Prostate Biopsy in an Era of Increasing Antimicrobial ResistanceLee, Kyueun / Drekonja, Dimitri M. / Enns, Eva A. et al. | 2018
- 318
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney DiseaseHabbous, Steven / Przech, Sebastian / Martin, Janet / Garg, Amit X. / Sarma, Sisira et al. | 2018
- 326
-
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?Malone, Daniel C. / Brown, Mary / Hurwitz, Jason T. / Peters, Loretta / Graff, Jennifer S. et al. | 2018
- 334
-
Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful UseHuo, Jinhai / Yang, Ming / Tina Shih, Ya-Chen et al. | 2018
- 341
-
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10, 000/QALY?Carroll, Christopher / Houten, Rachel / Boland, Angela / Kaltenthaler, Eva / Dickson, Rumona et al. | 2018
- 351
-
The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of HypertensionPeñaloza-Ramos, Maria Cristina / Jowett, Sue / Sutton, Andrew John / McManus, Richard J. / Barton, Pelham et al. | 2018
- 364
-
Associations of Smoking, Physical Inactivity, Heavy Drinking, and Obesity with Quality-Adjusted Life Expectancy among US Adults with DepressionJia, Haomiao / Zack, Matthew M. / Gottesman, Irving I. / Thompson, William W. et al. | 2018
- i
-
Table of Contents| 2018
- S2
-
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALSRamos, M. / Foos, V. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Lamotte, M. et al. | 2018
- S3
-
CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER: MAPPING FROM EPIC TO PORPUSZamora, V. / À, Pont / Garin, O. / Pardo, Y. / Ferrer Fores, M. et al. | 2018
- S4
-
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVECariou, C. / Tremblay, G. / Dolph, M. / Brandt, P.S. / Forsythe, A. et al. | 2018
- S5
-
CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)Van Vlaenderen, I. / Moeremans, K. / Van Bellinghen, L. et al. | 2018
- S6
-
DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDSHouben, E. / Heintjes, E. / Cremers, S. / Beekman, W. / Beest F, Penning-van / Stehouwer, C. / Herings, R. et al. | 2018
- S8
-
HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENTPisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
- S9
-
HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BAMacaulay, R. / Mohamoud, Z. / Schmidt, B. et al. | 2018
- S10
-
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMABlommestein, H. / van Beurden-Tan, C. / de Groot, S. / Blijlevens, N. / Sonneveld, P. / Groot CA, Uyl-de / Zweegman, S. / Franken, M.G. et al. | 2018
- S11
-
ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER'STsong, W. / Jones, E. / Pike, J. / Bluff, D. et al. | 2018
- S12
-
PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENTOstermann, J. / Derrick, C. / Yelverton, V. / Hobbie, A. / Weinhold, A. / Thielman, N. et al. | 2018
- S15
-
PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEWBhutani, M.K. / Rajora, P. / Soni, D. / Pan, J.J. et al. | 2018
- S16
-
PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITALMorales Perez, M. / Paladio-Hernandez, J.A. / Luna Mendoza, D. / Paredes-Garcia, P. / Munguia Juarez, L. / Sanchez Rodriguez, I. / Lopez-Luis, J. / Hernandez-Martinez, J. / Ramirez-Padilla, L. / Diaz-Rosales, S. et al. | 2018
- S17
-
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMARoskell, N. / Gregory, J. / Wisniewski, T. / Thompson, G.J. / De la Cruz, C. et al. | 2018
- S18
-
PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAINSuarez, J. / Juarez-Garcia, A. / Shaw, J.W. / Contente, M. / Polanco, C. et al. | 2018
- S19
-
PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES: A COMPARISON IN NON-SMALL CELL LUNG CANCERvan Hooijdonk, I.E. / Lai, L. / van Engen, A. et al. | 2018
- S20
-
PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERChowdhury, S. / Oudard, S. / Hadaschik, B.A. / Uemura, H. / Joniau, S. / Pilon, D. / Ladouceur, M. / Behl, A. / Liu, J. / Dearden, L. et al. | 2018
- S21
-
PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)Adedokun, L. / Penaloza-Ramos, C. / Lee, J. et al. | 2018
- S22
-
PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSLorenzi, M. / Amonkar, M. / Zhang, J. / Mehta, S. / Liaw, K. et al. | 2018
- S23
-
PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO: WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?Ben-Aharon, O. / Magnezi, R. / Leshno, M. / Goldstein, D.A. et al. | 2018
- S25
-
PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINAMacmullen, M. et al. | 2018
- S26
-
PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Garrido, S.D. / Nardi, E. / Alves, M. et al. | 2018
- S27
-
PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMABPoquet-Jornet, J.E. / Carrera Hueso, J. / Crespo, C. / Cuesta-Grueso, C. / Ramón Barrios, M.A. / Gasent-Blesa, J.M. / Fortuny-Organs, B. et al. | 2018
- S30
-
PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATAHupe, M.C. / Hammerer, P. / Ketz, M. / Kossack, N. / Colling, C. / Merseburger, A.S. et al. | 2018
- S31
-
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALYAgirrezabal, I. / Gaikwad, I. / Cirillo, L. / Lothgren, M. et al. | 2018
- S32
-
PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMAShah, M.V. / McGovern, A. / Hepp, Z. et al. | 2018
- S34
-
PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREAPark, M. et al. | 2018
- S37
-
PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLANDTsoumani, E. / D'Oca, K. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
- S38
-
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZILCarvalho, A.C. / Cao, Q. / van Asselt, A. / Sasse, A.D. / Postma, M.J. et al. | 2018
- S39
-
PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTSKourkoulas, N. / Athanasakis, K. / Kakouros, M. / Skroumpelos, A. / Kyriopoulos, J. et al. | 2018
- S40
-
PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCERZhou, Z. / Hu, X. et al. | 2018
- S41
-
PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLICDoležel, J. / Pour, M. / Skalický, D. / Fínek, J. et al. | 2018
- S42
-
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCERJansen, J.P. / Incerti, D. / Shafrin, J. / Frederickson, A.M. / Lakdawalla, D.N. / Reckamp, K.L. et al. | 2018
- S43
-
PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECEBourhis, F. / Eriksson, J. / Ruffo, P. / D'Agostino, P. / Turini, M. et al. | 2018
- S44
-
PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIAKrysanova, V. / Krysanov, I. / Ermakova, V. et al. | 2018
- S46
-
PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSISNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
- S47
-
PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?Farinella, M. / Rubinstein, J. / Inumerable, R.V. / Gizaw, N. / Ho, Y. et al. | 2018
- S48
-
PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE: AN INTERNATIONAL PERSPECTIVEKamal, K.M. / Covvey, J.R. / Mehta, Z. / Zacker, C. et al. | 2018
- S49
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORTSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S50
-
PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALYTucci, C. / Trimarchi, C. / Urbinati, D. / Demma, F. / Fico, M. / Fioravanti, L. et al. | 2018
- S51
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSISSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S52
-
PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVESKazaryan, I. / Sevikyan, A. / Amirkhanyan, A. / Melikyan, M. et al. | 2018
- S53
-
PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPELast, V. / Hickey, D.A. et al. | 2018
- S55
-
PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOWTolkushin, A. / Davydovskaya, M. / Ermolaeva, T. / Kokushkin, K. / Poliakova, K. et al. | 2018
- S56
-
PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5Rider, A. / Lewis, K. / Higson, O. et al. | 2018
- S58
-
PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.Solozabal, M. / De Prado, A. / Planellas, L. / Á, Baltasar-Sanchez / Carreño-Serra, A. / Callejo-Velasco, D. et al. | 2018
- S59
-
PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOMParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Mann, H. / Wang, H. et al. | 2018
- S60
-
PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONSLiden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
- S61
-
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONSZou, D. / Desrosiers, N. / Wu, S. / Prawitz, T. / Tervonen, T. / Marsh, K. / Caro, J.J. et al. | 2018
- S62
-
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAOmelyanovskiy, V. / Avxentyeva, M. / Sura, M. / Savilova, A.G. / Khachatryan, G.R. et al. | 2018
- S63
-
PCN292 - CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASEMayer, F. / Hodek, J. / Walzer, S. et al. | 2018
- S64
-
PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): PATIENTS', ONCOLOGISTS' AND NURSES' PERSPECTIVESDuracinsky, M. / Chassany, O. / Griffith, J. / Coblentz-Baumann, L. et al. | 2018
- S65
-
PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES: HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?Jonsson, B. / Chao, D. / Toumi, M. / Child, A. / Morris, J. / Hertel, N. et al. | 2018
- S66
-
PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS: A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.Filby, A. / Edwards, H.K. / Beggs, L. / O'Brien, S. et al. | 2018
- S67
-
PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGYLie, X. / Kempf, L. / van Engen, A. et al. | 2018
- S68
-
PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018): NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORTRebollo, P. / Hashim, M. / Gottschalk, F. / Ortega, T. / Heeg, B. / Wilke, T. et al. | 2018
- S69
-
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R. / Franceschetti, A. et al. | 2018
- S70
-
PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Hubanova, P. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
- S72
-
PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALSHuang, M. / Chandwani, S. / Insinga, R. / Burke, T. / Pellissier, J. / Pickard, A.S. et al. | 2018
- S73
-
PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTATHudgens, S. / Floden, L. / Leoni, M. / Nikonova, E. / Quaglino, P. et al. | 2018
- S74
-
PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCERGregory, J. / Dyer, M. / Hoyle, C. / Mann, H. / Hatswell, A.J. et al. | 2018
- S75
-
PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATAMerinopoulou, E. / Cooper, O. / Hareendran, A. / Booth, A. / Faulkner, E.C. / Spinner, D.S. / Bruno, A. / Arjunji, R. et al. | 2018
- S76
-
PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEWSparano, F. / Aaronson, N. / Cottone, F. / Piciocchi, A. / La Sala, E. / Anota, A. / Deliu, N. / Kieffer, J.M. / Efficace, F. et al. | 2018
- S79
-
PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATESEkwueme, D.U. / Pollack, L.M. / Hung, M. / Khushalani, J.S. / Miller, J.W. / Chang, S. et al. | 2018
- S82
-
PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?Karppinen, M.L. / Ihalmo, P. / Hjortsberg, C. et al. | 2018
- S83
-
PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIESNevins, J.F. / Colasante, W. / Rahmati, D. et al. | 2018
- S84
-
PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SETCooper, S. / Bouvy, J. / Boysen, M. / Robertson, J. et al. | 2018
- S86
-
PCP34 - BIOSIMILARS: WHAT'S THE ISSUE?Mahi, L. / Barral, G. et al. | 2018
- S88
-
PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELSGal, P. / Kovacs, V. et al. | 2018
- S90
-
PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASESSzabo, S.M. / Johnston, K.M. et al. | 2018
- S91
-
PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIESRylands, A.J. / Boxell, E. / Bottomley, C.J. et al. | 2018
- S93
-
PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE USTsang, Y. / Drake, W. / Pruett, J. et al. | 2018
- S94
-
PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?Oh, J. / Tsitarava, M. / Loh, F.E. et al. | 2018
- S96
-
PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYFanelli, F. / Gazzi, L. / Heiman, F. / Peduto, I. / Pegoraro, V. et al. | 2018
- S97
-
PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIARomero, M. / Marino, C. / Cruz, A.M. / Rigueros, J. et al. | 2018
- S98
-
PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINAGiorgi, M.A. / Boissonnet, C.P. / Micone, P.V. / Gallo, M. / Stuart, P. / Giglio, N.D. et al. | 2018
- S99
-
PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTINGStafylas, P. / Karaiskou, M. / Zouka, M. et al. | 2018
- S100
-
PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS: A RETROSPECTIVE DATABASE STUDYXu, Y. / Liu, H. / Gao, Y. / Xuan, J. et al. | 2018
- S102
-
PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLANDDudek, D.Z. / Lamotte, M. / Sawicka, M. / Huczek, Z.J. / Depukat, R. / Rajtar-Salwa, R. / Krupiarz, M. / Duma, K. / Sidelnikov, E. et al. | 2018
- S103
-
PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTSOrlowski, A. / Slater, R. / Ashton, R. / Glover, R. et al. | 2018
- S104
-
PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISKGarcía-Goñi, M. / Fácila, L. / Cinza, S. / Pinto, X. / Cortes, X. / Prades, M. / Aceituno, S. et al. | 2018
- S105
-
PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLICKolek, M. / Weber, J. / Karbusicka, M. / Vothova, P. / Mazan, P. / Duba, J. et al. | 2018
- S106
-
PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOMLaskier, V. / Guy, H. / Fisher, M. / Neuman, W.R. / Bucior, I. / Deitelzweig, S.B. / Cohen, A. et al. | 2018
- S107
-
PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY: A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONDawoud, D. / Wonderling, D. / Lewis, S. / Glen, J. / Griffin, X. / Reed, M. / Rossiter, N. / Stansby, G. / Hunt, B.J. / Chahal, J.K. et al. | 2018
- S108
-
PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)Annemans, L. / Azuri, J. / Al-Rasadi, K. / Al-Zakwani, I. / Daclin, V. / Mercier, F. / Danchin, N. et al. | 2018
- S109
-
PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES: DESPEGA STUDYAceituno, S. / Millan, J. / Rodriguez, P. / Rodríguez de Miguel, M. / Melogno Klinkas, M. / Orera - Peña, M.L. et al. | 2018
- S110
-
PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION: A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABANSchinle, P. / Keogh-Bootland, S. / du Feu, J. / Durno, K. / How, W.J. / Hill, N. / Gordon, J. / Sugrue, D. / Beresford, L. / Lister, S. et al. | 2018
- S111
-
PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAELWeitzman, D. / Bourvine, L. / Tirosh, M. / Shalev, V. / Chodick, G. et al. | 2018
- S112
-
PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINSAndretta, M. / Degli Esposti, L. et al. | 2018
- S113
-
PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTSKo, A. / Choi, S. / Chang, J. / Park, S.M. et al. | 2018
- S114
-
PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING: HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTIONJacobs, M.S. / van Hulst, M. / Campmans, Z. / Tieleman, R.G. et al. | 2018
- S115
-
PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATIONNatani, H. / Gogna, S. / Jindal, R. / Laires, P.A. / Cristino, J. et al. | 2018
- S116
-
PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)Afonso-Silva, M. / Laires, P.A. / Gonçalves, C. / Cary, M. / Guerreiro, J.P. / Romão, M. / Teixeira Rodrigues, A. et al. | 2018
- S117
-
PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONGLee, V.W. / So, S.C. / Yeo, J. / Yan, B.P. et al. | 2018
- S119
-
PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Sha'aban, A. / Mohamed Noor, D.A. et al. | 2018
- S120
-
PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONSBalijepalli, C. / Ayers, D. / Kandaswamy, P. / Ustyugova, A.V. / Pfarr, E. / Lund, S.S. / Druyts, E. et al. | 2018
- S122
-
PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE: A CLAIMS DATA ANALYSISGabler, M. / Picker, N. / Mueller, S. / Wilke, T. / Geier, S. / Försch, J. / Aberle, J. / Martin, S. / Riedl, M. et al. | 2018
- S123
-
PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETESOverbeek, J.A. / Kuiper, J.G. / van der Heijden, A.A. / Labots, M. / Haug, U. / Herings, R.M. / Nijpels, G. et al. | 2018
- S124
-
PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES &ENHANCEMENT PATIENT'S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASEAbotaleb, A. / Amin, M. et al. | 2018
- S125
-
PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAINSicras-Mainar, A. / Navarro-Artieda, R. et al. | 2018
- S126
-
PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
- S127
-
PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLICLoncak, V. / Bartak, M. / Rogalewicz, V. et al. | 2018
- S128
-
PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETESLanger, J. / Wolden, M.L. / Shimoda, S. / Sato, M. / Araki, E. et al. | 2018
- S129
-
PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRANDavari, M. / Khorasani, E. / Savari Shojaei, R. / Akbari, Sari A / Saiyarsarai, P. et al. | 2018
- S130
-
PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLICRussel-Szymczyk, M. / Parekh, W. / Rychna, K. / Pöhlmann, J. / Hunt, B. et al. | 2018
- S131
-
PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIABogdanovic, M. / Fournier, M. / Vitezic, D. et al. | 2018
- S132
-
PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
- S133
-
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMENFitria, N. / Utama, B. / Pradipta, I. / Schmidt, A. / van Asselt, A. / Postma, M.J. et al. | 2018
- S134
-
PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES: IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENTAscenção, R. / Fiorentino, F. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
- S135
-
PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK: A RETROSPECTIVE COHORT STUDYSpanopoulos, D. / Poole, C. / Barrett, B. / Busse, M. / Roman, T. / Khunti, K. et al. | 2018
- S137
-
PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDYDegli Esposti, L. / Perrone, V. / Saragoni, S. / Blini, V. / D'Avella, R. / Gasperini, G. / Lena, F. / Fanelli, F. / Gazzi, L. / Giorgino, F. et al. | 2018
- S138
-
PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALYMatza, L.S. / Osumili, B. / Stewart, K.D. / Perez, M. / Jordan, J. / Biricolti, G. / Romoli, E. / Losi, S. / Del Santo, S. / Spaepen, E. et al. | 2018
- S139
-
PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURESMcNamara, M. / Westhead, H. / Gross, H. / Turner-Bowker, D.M. / Yaworsky, A. / Pleil, A. / Loftus, J.V. et al. | 2018
- S140
-
PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLANDRuotsalainen, J. / Balcerzak, M. et al. | 2018
- S142
-
PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATIONOkumura, H. / Tang, W. / Iwasaki, K. / Shoji, S. / Odaka, T. / Nakajima, A. et al. | 2018
- S143
-
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACYMargusino-Framiñán, L. / Cid-Silva, P. / Mena-de-Cea, A. / Vazquez-Rodriguez, P. / Rodriguez-Osorio, I. / Lopez-Calvo, S. / Pernas-Souto, B. / Martin-Herranz, I. / Castro-Iglesias, A. et al. | 2018
- S147
-
PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTSSchmetz, A. / Petrakis, I. / Khalid, J.M. / Minda, K. / Agboton, C. / Rawson, K. / Baumgart, D.C. et al. | 2018
- S148
-
PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
- S149
-
PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS: RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)Balp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
- S151
-
PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE: VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIMEHöglinger, M. / Knöfler, F. / Scholz, S. / Schaumann-von Stosch, R. / Eichler, K. et al. | 2018
- S152
-
PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESSIpolyi, D. / Molnár, A. / Oláh, A. / Karácsony, I. / Pakai, A. / Brantmüller, É. / Boncz, I. / Breitenbach, Z. et al. | 2018
- S153
-
PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARYPónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
- S154
-
PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTSDesai, R.A. / Camacho, F. / Tan, X. / LeBaron, V. / Blackhall, L. / Balkrishnan, R. et al. | 2018
- S155
-
PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANYJones, C. / Cocklin, S.L. et al. | 2018
- S156
-
PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: A POLICY AND PIPELINE REVIEWCollings, H. / Palmer, T. / Tavella, F. et al. | 2018
- S157
-
PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT'S THE DIFFERENCE?Mueller, E. / Neeser, K. / Oelze, I. et al. | 2018
- S158
-
PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS: APPLY LIBERALLY OR USE SPARINGLY?Lockwood, C. / Rodrigues, T. / Ando, G. et al. | 2018
- S159
-
PHP56 - EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALYD'Ausilio, A. / Seyed Khoei, N. / Lanati, E.P. et al. | 2018
- S160
-
PHP62 - HOME BREWED AUTOLOGOUS THERAPIES: CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL & GENE THERAPY MANUFACTURERS?Khurana, S. / Kumar, A. / Sotou, D.S. et al. | 2018
- S161
-
PHP67 - CURRENT INITIATIVES & FUTURE OF E-HEALTH FUNDING PATHSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
- S162
-
PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARISAdé, A. / Degrassat-Théas, A. / Bocquet, F. / Parent de Curzon, O. / Paubel, P. et al. | 2018
- S163
-
PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPMMacaulay, R. / Fernandez Dacosta, R. et al. | 2018
- S165
-
PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECECherneva, D. / Benisheva, T. et al. | 2018
- S166
-
PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIAMittal, P. / Lai, K.Y. / Verma, R.K. / Hasan, S.S. et al. | 2018
- S167
-
PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATIONMoreno Juste, A. / Guarino, I. / Russo, V. / Menditto, E. et al. | 2018
- S168
-
PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPEVandewalle, B. / Félix, J. / Ferreira, C. et al. | 2018
- S170
-
PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS: A SURVIVAL MODEL ANALYSISCima, J. / Almeida, A.S. et al. | 2018
- S171
-
PHP128 - 3F - FORMULA FOR FUNDING: RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEMLourenço, A. / Ventura, C. / Andrade, S. / Sousa, J. / Valadas, F. et al. | 2018
- S173
-
PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE: IMPACT ON HTA OUTCOMES AND PRICEDehnen, J. / Petry, D. / Kruse, F. / Bercher, J. et al. | 2018
- S174
-
PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGALCorreia, S. / Yantsides, C. / Amorim, A.P. / Monteiro, J.L. / Costa, L. / Gonçalves, A.M. / Azevedo, A. / Paiva, J.A. et al. | 2018
- S175
-
PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY: A LITERATURE REVIEWFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
- S176
-
PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMESLewis, M. / Tavella, F. / Okhuoya, P. et al. | 2018
- S178
-
PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD: INITIAL ESTIMATES IN REPUBLIC OF BELARUSKozhanova, I. / Sachek, M. et al. | 2018
- S180
-
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVERLe Pen, C. / Sclison, S. / Ravonimbola, H. / Paolantonacci, J. / Baseilhac, E. / Savart, P. / Dorizon, D. / Vigneron, A. et al. | 2018
- S181
-
PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATIONRavindra, S. / Boehler, Y. et al. | 2018
- S182
-
PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES: A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018Glen, F. / Pulfer, A. et al. | 2018
- S184
-
PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Khogeer, B. / Anjarwalla, N. / Doolub, N. / Grosvenor, A. et al. | 2018
- S185
-
PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE: ISSUES AND WAYS FOR IMPROVEMENTDobrova, V. / Zupanets, I. / Shilkina, O. / Lishchyshyna, O. et al. | 2018
- S186
-
PHP217 - TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5López, N. / Prada, M. / Berard, I. / Schleich, W. / Melson, C. et al. | 2018
- S187
-
PHP222 - IDENTIFYING THE KEY DRIVERS AFFECTING THE REIMBURSEMENT OF THERAPEUTIC VACCINES IN EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Narjal, M. / Yadav, V. / Shah, C.S. et al. | 2018
- S189
-
PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS: NOT ALWAYS A NICE OUTCOMEGriffiths, E.A. et al. | 2018
- S190
-
PHP238 - CARER DISUTILITY: IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?Ferizovic, N. / Marshall, J.D. et al. | 2018
- S191
-
PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTSVandewalle, C. / Charoy, M. / Heurtebis, J. / Desplanches, L. / Gauthier, M. / de Sauvebeuf, C. et al. | 2018
- S192
-
PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN'S HEALTH QUESTIONNAIRE AGAINST THE EQ-5D-5L AND SF-6DKaambwa, B. / Ratcliffe, J. et al. | 2018
- S193
-
PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOLXia, A. / Schaefer, C. / Szende, A. / Jahn, E. / Dunlop, W. et al. | 2018
- S194
-
PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELINGMaskineh, C. / Becker, R.V. / Kosremelli Asmar, M. / Bekhazi, H. / Sleilaty, G. et al. | 2018
- S195
-
PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICEFerenczy, M. / Dudás, M. / Pakai, A. / Karácsony, I. / Boncz, I. / Rozmann, N. / Komlósi, K. / Oláh, A. et al. | 2018
- S197
-
PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACHPanni, T. / Thiele, A. / Carls, A. / Wallstab, A. / Eberle, K. / Schleibner, S. et al. | 2018
- S198
-
PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKSOyeye, O. / Johnson, K.I. et al. | 2018
- S199
-
PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTSWillemsen, A. / Estevão, S. / Dupree, R. et al. | 2018
- S200
-
PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Wordsworth, J. / Cork, D. / Curry, A. / Ralston, S. et al. | 2018
- S202
-
PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPEHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S203
-
PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCECabout, E. / Launois, R. et al. | 2018
- S204
-
PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?Ecker, T. et al. | 2018
- S207
-
PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANYGohlke, A. / Kostev, K. / Kuschel, A. et al. | 2018
- S208
-
PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVEHenriques, J. / Amorim, A. et al. | 2018
- S209
-
PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSISHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S210
-
PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGSRadu, P. / Stoica, I. / Udroiu, P. et al. | 2018
- S211
-
PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5Izmirlieva, M.A. / Reinaud, F. / Ando, G. et al. | 2018
- S212
-
PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICEMarsh, S.E. et al. | 2018
- S214
-
PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSISTaheri, S. / Varmaghani, M. / Heidari, E. / Yousefi, N. / Peiravian, F. et al. | 2018
- S216
-
PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALYKriz, A. / Migliore, A. / Wright, A. / Piaggio, T. et al. | 2018
- S223
-
PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOMWeidlich, D. / Hicks, M.D. / Floros, L. / Patel, J. / Charbonneau, C. / Sung, A.H. et al. | 2018
- S224
-
PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCEFievez, S. / Tin Tin Htar, M. / Goguillot, M. / Bénard, S. / Huang, L. et al. | 2018
- S225
-
PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTINGFerreira, J. / Pereira, R. / Schelfhout, J. / Jiang, Y. et al. | 2018
-
PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?Liden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
-
PCN218 - PERSONALIZED THERAPY DEVELOPMENT IN NSCLC DEMONSTRATES INTERSECTION BETWEEN INNOVATION AND POSITIVE COVERAGE DECISIONSEslami, N. / Lehmann, H. / Garfield, S. / Erickson, G. et al. | 2018
-
PCN226 - BIOSIMILARS AND THE REGULATION OF ONCOLOGICAL PREPARATIONS IN GERMANYWalendzik, A. / Wasem, J. / Altin, S. / Bauer, C. / May, U. et al. | 2018
-
PCN155 - COST-EFFECTIVENESS OF CPX-351 VERSUS 3+7 AMONG PATIENTS <60 YEARS OF AGE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED KINGDOM (UK)Kansal, A. / Reifsnider, O. / Khankhel, Z. / Todorova, L. / Dorman, E. / Coughlan, A. / Hoog, M. / Villa, K. et al. | 2018
-
PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEYÖksüz, E. / Malhan, S. / Yanik, L. / Koc, E. / Erdogan-Ciftci, E. / Guler, B. / Orfanos, P. et al. | 2018
-
PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN'S LYMPHOMA: A COST-EFFECTIVENESS ANALYSISRaymakers, A. / Costa, S. / Peacock, S.J. / Regier, D. et al. | 2018
-
PCN141 - COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECEVellopoulou, K. / Tzanetakos, C. / Theodoropoulou, T. / Akratos, A. / Maniadakis, N. et al. | 2018
-
PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATESSkinner, K.E. / Dufour, R. / Haiderali, A. / Huang, M. / Schwartzberg, L.S. et al. | 2018
-
PCN134 - USE OF LIQUID BIOPSY IN METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: A COST CONSEQUENCE ANALYSIS.Gancitano, G. / Almeida Gerolami, G. / Ravasio, R. / Cortinovis, L.D. / Dionisi, M. et al. | 2018
-
PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIAWalter, E. / Hausberger, S. / Lazic-Peric, A. et al. | 2018
-
PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCELafuma, A. / Cotté, F. / Le Tourneau, C. / Emery, C. / Gaudin, A. / Torreton, E. / Gourmelen, J. / Bonastre, J. et al. | 2018
-
PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEWCherepanov, D. / Kayaniyil, S. / Huang, H. / Romanus, D. / Labotka, R. / Zagadailov, E. / Khan, Z. et al. | 2018
-
PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECESiskou, O. / Vasilakopoulos, T. / Galanis, P. / Tsirigotis, P. / Batsis, I. / Terpos, E. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN79 - DECISION IMPACT OF A 21-GENE SIGNATURE IN EARLY BREAST CANCER: A NATURAL EXPERIMENT USING ROUTINE DATATramonti, G. / Gray, E. / Sims, A.H. / Hall, P.S. et al. | 2018
-
PCN57 - THE ASSOCIATION BETWEEN METFORMIN EXPOSURE AND SURVIVAL AMONG DIABETIC PATIENTS WITH NON-SMALL CELL LUNG CANCERRuban, C. / Blanchette, C.M. / Howden, R. / Kowalkowski, M. / Marino, J. / Saunders, W.B. et al. | 2018
-
PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISONCope, S. / Popoff, E. / Keeping, S. / Goldgrub, R. / Jansen, J.P. / Penrod, J.R. / Abraham, P. / Camidge, D.R. / Korytowsky, B. / Gu, T. et al. | 2018
-
PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING: IMPLICATIONS FOR RECRUITMENTHalhol, S. / Booth, A. / Pan, S. / Cox, A. / Merinopoulou, E. et al. | 2018
-
ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON'S DISEASECabout, E. / Kabeshova, A. / Launois, R. / Houeto, J. et al. | 2018
-
PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCERDavies, A.D. / Chang-Douglass, S. et al. | 2018
-
PCV29 - REAL-WORLD DOAC AND VKA USE: THE PHARMO-ANTICOAGULATION COHORTSmits, E. / Evers, J. / Penning-van Beest, F.J. / Herings, R.M. / Bezemer, I.D. et al. | 2018
-
PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINESha'aban, A. / Zainal, H. / Muhamad, A.S. / Hammad, M.A. / Ibrahim, B. et al. | 2018
-
PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015Wahler, S. / Koll, C. / Müller, A. et al. | 2018
-
PCP47 - TAMING THE TORNADO CHART: SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELSO'Day, K. / Mezzio, D. et al. | 2018
-
PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?Pisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
-
PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITYGonzalez-Barba, F. / Sat-Muñoz, D. / Balderas-Peña, L. / Trujillo-Hernández, B. / Martinez-Herrera, B. / Bayardo-López, L.H. / López-Almaraz, L.M. / Salazar-Páramo, M. / Alvarado-Zermeño, A. / Hernández-Chávez, G.A. et al. | 2018
-
PCN337 - HR+/HER2− ADVANCED BREAST CANCER TREATMENT, DISEASE PROGRESSION, AND SURVIVAL IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, AND MEXICOKurosky, S. / Levine, C. / Kaye, J.A. / Esterberg, E. / Suarez, L.A. / Zhan, L. / Iyer, S. et al. | 2018
-
PCP29 - BRAZILIAN PHARMACEUTICAL CLINICAL SERVICES: A DOCUMENTARY ANALYSISChagas, M.O. / Porto, C.C. / Chaveiro, N. / Noll, M. / Assis, D.L. / Chagas, F.A. / Chagas, V.O. et al. | 2018
-
PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITYMartinez-Herrera, B. / Sat-Muñoz, D. / Balderas-Peña, L. / Trujillo-Hernández, B. / Gonzalez-Barba, F. / Solórzano-Meléndez, A. / Bayardo-López, L.H. / Alvarado-Zermeño, A. / Hernández-Chávez, G.A. / Salazar-Páramo, M. et al. | 2018
-
PCN311 - EUROPEAN MARKET ACCESS CHALLENGES FOR RELAPSED REFRACTORY MULTIPLE MYELOMA TRIPLET THERAPIESStefani, I. / Brough, A. / McKee, E. / Lyons, E. et al. | 2018
-
PCN278 - DIVERSITY OF PATIENTS PATHWAYS WITH LUNG CANCER BETWEEN 4 FRENCH REGIONS: DEFINITION OF DISSIMILARITY MEASURESProdel, M. / Blein, C. / Fernandes, J. / Chouaid, C. et al. | 2018
-
PCN130 - COST ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) – A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANYMayerhoff, L. / Lehne, M. / Hickstein, L. / Salimullah, T. / Prieur, S. / Thomas, S.K. / Zhang, J. et al. | 2018
-
PCN118 - THE BURDEN OF CANCER IN SPAINBadia, X. / Tort, M. / Camps, C. / Diaz Rubio, E. et al. | 2018
-
CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATARueda, J. / Valencia, C.F. / Mullins, C.D. / Onukwugha, E. / Zhan, M. / Slejko, J.F. et al. | 2018
-
PHP370 - AMBULATORY CARE TRENDS IN THE EMERGENCY DEPARTMENTBuchenberger, J.D. / Noone, J.M. / Abrigo, M.B. et al. | 2018
-
PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN: ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVESAkiyama, S. / Murata, T. / Kidoguchi, Y. / Osuga, Y. et al. | 2018
-
PHP361 - PIM AND EAMS: THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESSNikolettos, J. / Gapper, A. et al. | 2018
-
PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMYLeaper, D.J. / Holy, C.E. / Chen, B.P. / Ghosh, E. / Edmiston, C.E. et al. | 2018
-
PHP192 - HTA EDUCATIONAL NEEDS IN CENTRAL-EASTERN-SOUTH EUROPEAN (CESE) COUNTIRES – RESULTS OF JOC HTA PROJECTHermanowski, T.R. / Zawada, A. et al. | 2018
-
PHP187 - BEST PRACTICES FOR REAL WORLD EVIDENCE (RWE) COLLECTION FOR CELL AND GENE THERAPIESKhurana, S. / Kumar, A. et al. | 2018
-
PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALSCharonis, A. / Papageorgiou, M. / Kontoudis, I. / Karokis, A. et al. | 2018
-
PHP162 - LICENCED ORPHAN MEDICINES EXPENDITURE IN TURKEYNacar, S. / Atikeler, K. / Beyan, A. / Safak Yilmaz, E. / Bayar, B. / Vural, I.M. et al. | 2018
-
PHP166 - TOOLS OF THE TRADE: PAYER APPROACHES TO HIGH PATIENT VOLUME, PREMIUM PRICED THERAPIESVassoler, H. / Spoors, J. et al. | 2018
-
PHP104 - PRESCRIPTION DRUG USE AND INAPPROPRIATE PRESCRIBING AMONG PREGNANT WOMEN IN SOUTH KOREAKim, A. / Lee, H. / Kang, H. et al. | 2018
-
PHP107 - THE STRUCTURE OF CONSUMPTION OF ANTIMICROBIAL DRUG FOR SYSTEMIC USE IN MULTIDISCIPLINARY HOSPITALS IN ST.PETERSBURG IN 2014-2015Gomon, J. / Kolbin, A. / Kurylev, A. et al. | 2018
-
PHP42 - EARLY ACCESS PROGRAMS: A COMPARISON BETWEEN FRANCE, GERMANY AND THE UNITED KINGDOMBen Younes, K. / Foix Colonier, A. / Amzal, B. / Angehrn, Z. / Karcher, H. et al. | 2018
-
PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017López, N. / Pomares, E. / Cuesta, M. et al. | 2018
-
PHP9 - PATIENT INVOLVEMENT IN THE DRUG LIFE CYCLE ACCORDING TO STAKEHOLDERS: EXPLORING THE GAP BETWEEN THEORY AND PRACTICEJanssens, R. / van Overbeeke, E. / Verswijvel, L. / Meeusen, L. / Coenegrachts, C. / Pauwels, K. / Dooms, M. / Stevens, H. / Simoens, S. / Huys, I. et al. | 2018
-
PHP5 - DEVELOPMENT OF THE PATIENT ORGANISATION SUBMISSION PROCESS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE), IRELANDHanevy, A. / Gorry, C. / Tilson, L. / O'Leary, A. / Barry, M. et al. | 2018
-
PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS: A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASEPeyerl, F.W. / Shenoy, A. / Hayashida, D.K. / D'Souza, F.T. et al. | 2018
-
PGI42 - NON-PERSISTENCE WITH IMMUNOSUPPRESANT, ANTI-TUMOR NECROSIS FACTOR, AND ANTI-INTEGRIN AGENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY: CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITUREFigueira, A. / Gomes, I. / Sequeira, C. / Silva, S. / Machado, F. / Figueiredo, J. / Rabadão, E. / Dinis, P. / Andreozzi, V. / Vandewalle, B. et al. | 2018
-
PDB122 - THE EFFECTS OF TYPE 2 DIABETES ON HEALTH-RELATED QUALITY OF LIFE IN THE FINNISH POPULATION AS MEASURED WITH EQ-5D-5LJalkanen, K. / Aarnio, E.J. / Lavikainen, P.T. / Jauhonen, H.M. / Enlund, H. / Martikainen, J.A. et al. | 2018
-
PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETESRamos, M. / Foos, V. / Ferrufino, C. / Yu-Isenberg, K. / Lamotte, M. et al. | 2018
-
PGI31 - PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION: REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAELSergienko, R. / Schwartz, D. / Odes, S. / Greenberg, D. et al. | 2018
-
PDB126 - FACTORS INFLUENCING FOOD CHOICES OF PEOPLE WITH TYPE 2 DIABETES: A Q METHODOLOGY STUDYHubens, K. / van Exel, N.J. et al. | 2018
-
PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPTHamdy El-sisi, G. / Emad, S. / Hamed, A. et al. | 2018
-
PHP330 - REAL-WORLD DATA COLLECTION ON MEDICAL DEVICES IN THE ERA OF VALUE-BASED HEALTHCARE: A LITERATURE REVIEWRizzo, E. / Buseghin, G. / Greco, T. / Murphy, J. / Pinciroli, M. / Mordenti, G. et al. | 2018
-
PHP329 - THE REGISTRY EVALUATION AND QUALITY STANDARDS TOOL (REQUEST) FOR HEALTH TECHNOLOGY ASSESSMENT FROM AN OUTCOMES ASSESSMENT PERSPECTIVEGimenez, E. / Espallargues, M. / Rodrigues, J. / Varela, L. / Patrick, H. / Jae, L. / Maja, V. / Guzina, I. et al. | 2018
-
PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017): THE CASE OF BULGARIABenisheva Dimitrova, T. / Stoimenova, A. / Sidzhimova, D. / Atanasova, R. et al. | 2018
-
PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)Ballini, L. / Bonvicini, L. / Bottazzi, P. / Eisenmann, A. / Formoso, G. / Giorgi Rossi, P. / Rosian-Schikuta, I. / Venturelli, F. / Vicentini, M. / De Laet, C. et al. | 2018
-
PHP297 - CHANGES IN ULTRA-ORPHAN DRUG ASSESSMENTS IN POLANDVaithyanathan, G. / Dekkers, R. / van Engen, A. et al. | 2018
-
PHP275 - ORPHAN MEDICINAL PRODUCTS GIVEN AN INITIAL NEGATIVE RECOMMENDATION BY NICE'S STA PROCESS BUT APPROVED FOLLOWING RE-EVALUATION IN ENGLANDForsyth, C. et al. | 2018
-
PHP293 - ORPHAN DRUGS IN GERMANY - LESSONS LEARNED FROM AMNOG, BEST AND WORST PRACTICES AND STRATEGIC IMPLICATIONSKirchmann, T. / Ewald, A. / Schönermark, M. et al. | 2018
-
PHP285 - EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKINGShih, T. / Toor, K. / Yoon, L. / Barron, R. / Cope, S. / Huber, C. / Arellano, J. / Jansen, J.P. et al. | 2018
-
PHP287 - GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONSKirchmann, T. / Schönermark, M. / Ewald, A. et al. | 2018
-
PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS: COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?Hnoosh, A. / Courmier, D.F. et al. | 2018
-
PHP244 - BRIDGING THE GAP: ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLANDFerizovic, N. / Hughes, T. et al. | 2018
-
PHP242 - AN ANALYSIS OF THE TIMELINES THROUGHOUT THE REIMBURSEMENT PATHWAY FOR DRUGS IN IRELANDConnolly, E. / Lamrock, F. / O'Donnell, H. / Walsh, C. / Tilson, L. / Barry, M. et al. | 2018
-
PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIABogdanovic, M. / Mihajlović, J. / Fournier, M. et al. | 2018
-
PDB93 - IMPACT OF CARDIOVASCULAR DISEASE ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTINGWeng, W. / Tian, Y. / Kong, S.X. / Ganguly, R. / Hersloev, M. / Brett, J. / Hobbs, T. et al. | 2018
-
PDB60 - COST-CONSEQUENCE ANALYSIS FOR RECOMBINANT HUMAN GROWTH HORMONE TREATMENT ADMINISTERED VIA DIFFERENT DEVICES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN ITALYCentonze, C. / Foo, J. / Vlachaki, I. / Novelli, P. et al. | 2018
-
PDB59 - COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC (IDEG) U100 FROM CURRENTLY AVAILABLE BASAL INSULINS IN BELGIUM BASED ON EVIDENCE FROM REAL-WORLD CLINICAL PRACTICEOlivieri, A. / Vandebrouck, T. / Hvid, C. et al. | 2018
-
PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
-
PDB29 - TYPE 2 DIABETES: DISCONTINUATION OF ANTIDIABETIC DRUG DISPENSING 8 YEARS AFTER STARTING TREATMENT: A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)Aguade, A. / Gastaldi-Menager, C. / Karsenty, D. / Semenzato, L. / Fontaine, P. / Fagot-Campagna, A. et al. | 2018
-
PDB37 - BUDGET IMPACT ANALYSIS OF THE ADULT TYPE 1 DIABETES MELLITUS NATIONAL CLINICAL GUIDELINE IN IRELANDCarty, P. / O'Neill, M. / Harrington, P. / Smith, S. / Ryan, M. et al. | 2018
-
PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV112 - PATTERN OF USE OF ANTIHYPERTENSIVE DRUGS IN TWO EUROPEAN COUNTRIES: COMPARISON OF THE INDEX THERAPIES AND PERSISTENCEMalo, S. / Aguilar, I. / Russo, V. / Feja, C. / Orlando, V. / Rabanaque, M. / Lallana, M. / Menditto, E. et al. | 2018
-
PCV116 - DISCONTINUATION AND HEALTH CARE RESOURCE UTILISATION IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN OR WARFARIN IN ENGLANDGraham, S. / Raluy-Callado, M. / Donaldson, R. / Colby, C. / Carroll, R. / Nordstrom, B. / Stynes, G. / Hill, N. / Ramagopalan, S. / Alikhan, R. et al. | 2018
-
PCV107 - MULTI-CRITERIA DECISION ANALYSIS (MCDA) - DISCUSSION ABOUT THE INCORPORATION OF RIOCIGUAT IN THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) UNDER THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)Carvalho, D.N. / Etto, H.Y. / Kim, H.S. / Nakada, C. / ÉJ, Peixoto de Miranda / Tannus, G. et al. | 2018
-
PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017Németh, N. / Endrei, D. / Elmer, D. / Horváth, L. / Csákvári, T. / Pónusz, R. / Boncz, I. et al. | 2018
-
PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINALin, Z. / Zhang, L. / Yang, X. / Liu, L. / Xuan, J. et al. | 2018
-
PCN261 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH COLORECTAL CANCER IN SPAINPlanellas, L. / Solozabal, M. / Barrull, C. / De Prado, A. / Canal-Díaz, N. / Gómez-Navarro, V. et al. | 2018
-
PIH52 - AN INVESTIGATION INTO THE CONTENT VALIDITY AND FEASIBILITY OF THE EQ-5D-5L, SF-12, WEMWBS AND ONS-4 IN MEASURING THE QUALITY OF LIFE AND WELLBEING OF OLDER ADULTS.Penton, H. / Young, T. / Dayson, C. / Hulme, C. et al. | 2018
-
PCN390 - METASTATIC COLORECTAL CANCER (MCRC) - LITERATURE REVIEW ON QUALITY OF LIFE INSTRUMENTSLebioda, A. / Krieger, T. / Kuhn, A. et al. | 2018
-
PCN385 - QUALITY OF LIFE OF PATIENTS LIVING WITH METASTATIC COLORECTAL CANCER (MCRC): EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER (EORTC) QUESTIONNAIRE RESULTS FROM A REAL WORLD EUROPEAN SURVEYBenedict, A. / Rakonczai, P. / Muszbek, N. / Maravic, Z. et al. | 2018
-
PIH28 - ISAACUS DATA LAKE PRE-PRODUCTION PROJECT: CHILD PLACEMENT DECISION AND ITS COST DRIVERSHallinen, T. / Soini, E. / Tirkkonen, J. / Kekoni, A. et al. | 2018
-
PHP362 - DO ALL RESEARCH GROUPS ALIGN ON THE VALUE OF AN INTERVENTION? CONCORDANCE OF COST-EFFECTIVENESS FINDINGS BETWEEN ICER REPORTS AND OTHER PUBLICATIONSSussman, M. / Yu, J. / Menzin, J. et al. | 2018
-
PHP213 - A RETROSPECTIVE REVIEW OF REIMBURSEMENT DECISIONS BY THE HAUTE AUTORITÉ DE SANTÉ IN 2017 - UNDERLYING RATIONALE FOR MEDICINAL PRODUCTS WITH INSUFFICIENT ACTUAL MEDICAL BENEFITMurphy, E.M. / Nwokoro, E. / Stanway, V.E. et al. | 2018
-
PHP197 - AN EVALUATION OF THE PERFORMANCE OF HOSPITAL PHARMACIES' GROUP PURCHASING ORGANIZATION TO PROMOTE HEALTHCARE MANAGEMENTPeikanpour, M. / Babapour, J. / Peiravian, F. et al. | 2018
-
PHP204 - VALIDATION OF A MULTICRITERIA DECISION ANALYSIS (MCDA) FRAMEWORK TO INCORPORATE THE PATIENTS' PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENTGálvez, M. / Saldaña, R. / Palacios, M. / Badia, X. et al. | 2018
-
PHP184 - PATIENT INFLUENCE ON BIOSIMILAR UPTAKE: THE NOCEBO EFFECTPovsic, M. / Lavelle, P. / Enstone, A. / Rousseau, B. et al. | 2018
-
PHP171 - REVISITING REIMBURSED DRUGS WITH ALTERNATIVE PAYMENT MODEL IN TURKEY: 2016-2018Demir, O. / Senturk, A. / Kahveci, R. et al. | 2018
-
PHP152 - MECHANISMS OF ILLEGAL EXPORT CAUSING DRUGS SHORTAGES IN POLANDKapuśniak, A. / Caban, A. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP142 - SEVERITY ADJUSTED PROBABILITY OF BEING COST-EFFECTIVE: A NOVEL APPROACH TO INTEGRATE SEVERITY AND COST-EFFECTIVENESS WITH APPLICATIONS TO NORWAY AND THE NETHERLANDSVersteegh, M. / Corro Ramos, I. / Buyukkaramikli, N. / Ansaripour, A. / Reckers-Droog, V. / Brouwer, W. et al. | 2018
-
PHP100 - UTILIZATIONS AND EXPENDITURES OF TUMOR NECROSIS FACTOR ANTAGONISTS IN MEDICARE PART D: CROSS- SECTIONAL STUDY (2014-2015)Alghamdi, A. / Alduraibi, D. et al. | 2018
-
PHP57 - EUROPEAN CONDITIONAL MARKETING AUTHORIZATION – DOES EARLY MARKETING AUTHORIZATION TRANSLATE INTO EARLY REIMBURSEMENT AND PATIENT ACCESS?Macaulay, R. / Rothwell, S. / Sutcliffe, D. et al. | 2018
-
PHP66 - CURRENT OPPORTUNITIES AND CHALLENGES IN MARKET ACCESS OF E-HEALTH SOLUTIONSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
-
PHP34 - TIME ANALYSIS OF THE DRUG APPROVAL PROCESS IN EUROPEMartínez-Rodríguez, I. / Uría, E. / Pomares, E. / Cuesta, M. et al. | 2018
-
PHP40 - TRENDS IN THE INCLUSION OF NON-PHARMACEUTICAL HEALTH TECHNOLOGIES IN THE ISRAELI NATIONAL LIST OF HEALTH SERVICESTriki, N. / Samama, E. / Luxenburg, O. / Porath, A. / Ash, N. et al. | 2018
-
PHP15 - NEW TREATMENT METHODS AND REIMBURSEMENT: EXPERIENCES IN GERMANY 2018Oelze, I. / Neeser, K. / Mueller, E. et al. | 2018
-
PGI41 - CLINICAL CHARACTERISTICS OF BIOLOGIC TREATED CROHN'S DISEASE PATIENTS WITH AND WITHOUT PRIOR SURGERY IN EUROPEAN UNIONKarki, C. / Lu, Y. / Sharma, N. / Triggs, H. et al. | 2018
-
PHP2 - CHARACTERISTICS OF DOCTOR-SHOPPERS: A SYSTEMATIC LITERATURE REVIEWBiernikiewicz, M. / Taieb, V. / Toumi, M. et al. | 2018
-
PGI16 - THE ECONOMIC BURDEN OF CHRONIC INFLAMMATORY BOWEL DISEASE PATIENTS IN FINLANDTorvinen, S. / Ventola, H. / Herrala, S. / Schmidt, S. / Ylisaukko-oja, T. / Voutilainen, M. et al. | 2018
-
PGI19 - STANDARD-DOSE PROTON PUMP INHIBITOR IN THE INITIAL NON-ERADICATION TREATMENT OF DUODENAL ULCER: SYSTEMATIC REVIEW, NETWORK META-ANALYSIS, AND COST-EFFECTIVENESS ANALYSISZhang, J. / Xie, J. et al. | 2018
-
PGI9 - SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EFFICACY OF INFLIXIMAB BIOSIMILARS IN INFLAMMATORY BOWEL DISEASE PATIENTSKaravitaki, M. / Kani, C. / Deutsch, M. / Markantonis, S. et al. | 2018
-
PGI15 - HEALTHCARE RESOURCE UTILIZATION (HCRU) IN METASTATIC OR UNRESECTABLE GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER PATIENTS RECEIVING SECOND-LINE TREATMENTGomez-Ulloa, D. / Amonkar, M. / Kothari, S. / Cheung, W.Y. / Chau, I. / Zalcberg, J.R. / Nuria, L. / Falcone, A. et al. | 2018
-
PDB106 - ASSESSING THE HEALTH AND ECONOMIC IMPACT OF PHARMACEUTICAL CARE IN ELDERLY PATIENTS WITH DIABETES: A SYSTEMATIC LITERATURE REVIEWObeng, G.D. / Inotai, A. / Hankó, B. / Ágh, T. / Csanádi, M. et al. | 2018
-
PDB133 - CHRONIC KIDNEY DISEASE, HEALTH MEASURES AND HEALTHCARE UTILIZATION AMONG ADULTS WITH DISBETES IN THE UNITED STATESMeraya, A.M. et al. | 2018
-
PDB118 - SYSTEMATIC EDUCATION IN PATIENTS WITH T2DM SIGNIFICANTLY IMPROVES ADHERENCE TO THE TREATMENT. THE ADVICE STUDYDoupis, J. / Alexandrides, T. / Elisaf, M. / Melidonis, A. / Bousboulas, S. / Thanopoulou, A. / Pagkalos, E.M. / Pappas, A. / Arvaniti, E. / Karamousouli, E. et al. | 2018
-
PHP325 - ORPHAN DRUGS' MARKET ACCESS CHALLENGES IN EUROPE FROM A GERMAN PERSPECTIVEKirchmann, T. / Ewald, A. / Schönermark, M. et al. | 2018
-
PHP282 - NEW AIFA INNOVATION ALGORITHM: IS IT REALLY A STEP FORWARD IN ALIGNING AIFA'S DECISION WITH EUROPEAN HTAS?Digiacomo, F. / Capuano, C. / Walsh, K. / Yampolsky, D. et al. | 2018
-
PHP290 - IMPLICATIONS OF CONDITIONAL APPROVAL AND APPROVAL UNDER EXCEPTIONAL CIRCUMSTANCES BY THE EUROPEAN MEDICINES AGENCY ON NICE APPRAISALSNeez, E. / Naci, H. / Pinilla, P. / Osipenko, L. / Mossialos, E. et al. | 2018
-
PHP272 - QUANTITATIVE ASSESSMENT OF TECHNICAL ERRORS FOUND IN ECONOMIC MODELS SUBMITTED TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Radeva, D. / Hopkin, G. / Naci, H. / Borrill, J. / Osipenko, L. / Mossialos, E. et al. | 2018
-
PHP267 - LANDSCAPE ASSESSMENT OF PROSPECTIVE REAL-WORLD EVIDENCE STUDIES IN EUROPEKönig, C. / Krinke, K. / Haas, J.S. / McLeod, K. / Braun, S. et al. | 2018
-
PHP230 - EU5 MARKET ACCESS FOR MEDICINES APPROVED UNDER EXCEPTIONAL CIRCUMSTANCESMycka, J. / Lobb, W. / Dellamano, R. / Dalal, N. / Dellamano, L. / Pereira, E. et al. | 2018
-
PHP229 - EU5 MARKET ACCESS FOR MEDICINES WITH CONDITIONAL MARKETING AUTHORISATIONSMycka, J. / Dellamano, R. / Lobb, W. / Dalal, N. / Dellamano, L. / Pereira, E. et al. | 2018
-
PHP221 - CONDITIONAL APPROVAL: ARE PAYERS REWARDING THESE HIGHLY NEEDED PHARMACEUTICALS?Auluck, J. / Conti, C.C. et al. | 2018
-
PDB97 - TYPE 2 DIABETES: OUTCOME OF DRUG TREATMENT IN PATIENTS INITIATING AGLP1 IN 2012: REAL-LIFE STUDY BASED ON SNIIRAM DATASemenzato, L. / Karsenty, D. / Aguade, A. / Fagot-Campagna, A. / Brun Buda, H. / Surroca, M. et al. | 2018
-
PDB88 - ADVENT OF MOBILE PLATFORMS LEVERAGES MULTISTAKEHOLDER COLLABORATION TO DRIVE OUTCOMES IN DIABETESEslami, N. / Marcarelli, A. / Zaidi, Q. / Garfield, S. et al. | 2018
-
PDB87 - A COST-OF-CONTROL ANALYSIS: ONCE-WEEKLY SEMAGLUTIDE REDUCES COST OF REACHING TREATMENT TARGETS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN NORWAYHamidi, V. / Sverre, J.M. et al. | 2018
-
PDB77 - LONG-TERM COST-EFFECTIVENESS ANALYSIS OF IDEGLIRA VERSUS IGLARLIXI FOR THE TREATMENT OF PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN IN THE ITALIAN SETTINGMontagnoli, R. / Lastoria, G. / Parekh, W. / Pöhlmann, J. / Hunt, B. et al. | 2018
-
PDB72 - PLATELET-RICH PLASMA IN DIABETIC FOOT ULCERS: COST-EFFECTIVENESS ANALYSIS FOR SPAINLinertová, R. / Del Pino Sedeño, T. / García-Pérez, L. / Aragón-Sánchez, J. / Kaiser-Girardot, S. / Trujillo-Martín, Md / Serrano-Aguilar, P. et al. | 2018
-
PCV144 - EFFECT OF CONVENIENCE OF ORAL ANTICOAGULANT THERAPY ON MEDICATION ADHERENCE: RESULTS OF AN INTERNATIONAL STATED PREFERENCE SURVEYVaanholt, M.C. / Weernink, M.G. / von Birgelen, C. / Groothuis-Oudshoorn, C.G. / IJzerman, M. / van Til, J.A. et al. | 2018
-
PDB5 - EFFECT OF STATINS USAGE ON INCIDENCE OF PERIPHERAL NEUROPATHY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Zaitoun, M. / Mohamed Noor, D.A. et al. | 2018
-
PCV97 - HEARTH FAILURE IN VENETO REGION, ITALY: ANALYSIS OF THE THERAPEUTIC PATHWAYS AND CONSUMPTION OF HEALTH CARE RESOURCESDegli Esposti, L. / Perrone, V. / Sangiorgi, D. / Pitotti, C. / Ritrovato, D. / Menti, A.M. / Andretta, M. et al. | 2018
-
PCV70 - EFFECT OF TIME IN THERAPEUTIC RANGE ON COST AND CLINICAL OUTCOMES OF ATRIAL FIBRILATION PATIENTS : A COST-CONSEQUENCES ANALYSIS OF RIVAROXABAN VS WARFARIN FOR TURKEYKockaya, G. / Cavus, F. / Ozin, B. / Yilmaz, K.C. / Ciftci, O. / Oguzhan Ergın, G. / Sharaf, A. / Buyuktuna, N. / Buyukisik, T. / Saylan, M. et al. | 2018
-
PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTSDamen, D. / Templin, C. / Ulrich, S. / Kulp, W. et al. | 2018
-
PCN270 - HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH 6 PREVALENT CANCER IN SPAIN, A REALWORLD DATA STUDYCallejo-Velasco, D. / Planellas, L. / Solozabal, M. / Barrull, C. / Canal-Díaz, N. / De Prado, A. et al. | 2018
-
PCN215 - EMERGING TRENDS IN THE MANAGEMENT OF NSCLC PD-L1+ PATIENTS IN ITALYTrimarchi, C. / Arenga, A. / De Santo, E. / Urbinati, D. et al. | 2018
-
PCN200 - COST-OFFSETS ASSOCIATED WITH THE NEW TRIPLETS AVAILABLE FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA AND RESOURCE CONSUMPTION DERIVED FROM ITALIAN REAL PRACTICERipellino, C. / Peduto, I. / Heiman, F. / Fioravanti, L. / Rea, M. / Demma, F. et al. | 2018
-
PCN257 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) FOLLOWING INITIAL PLATINUM THERAPY IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC): A MEDICAL RECORD REVIEW IN GERMANYParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Sawyer, W. / Wang, H. et al. | 2018
-
PCN178 - COST-EFFECTIVENESS OF PEMBROLIZUMAB AS SECOND-LINE TREATMENT FOR PATIENTS WITH ADVANCED UROTHELIAL CANCER IN FRANCERobert, J. / Culine, S. / Roupret, M. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. / Lafuma, A. / Bensimon, L. / Clement, A. et al. | 2018
-
PCN119 - SECONDARY CARE RESOURCE UTILIZATION AND COST OF CARE AMONG FINNISH NON-SMALL CELL LUNG CANCER PATIENTSLoponen, H. / Vihervaara, V. / Ylä-Viteli, S. / Torvinen, S. / Tamminen, K. / Ylisaukko-oja, T. / Silvoniemi, M. et al. | 2018
-
PCN128 - COSTS OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) – A RETROSPECTIVE ANALYSIS OF JAPANESE CLAIMS DATAWakase, S. / Tsuchiya, S. / Yoshimura, M. / Zhang, J. et al. | 2018
-
PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CANADIAN SOCIETAL PERSPECTIVEYang, H. / Zhang, J. / Hampe, M. et al. | 2018
-
PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Sá, A.B. / Santos, B.R. / Nardi, E. / Alves, M. et al. | 2018
-
PCN89 - COST –EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2 + BREAST CANCER IN REPUBLIC OF MACEDONIAKapedanovska Nestorovska, A. / Sterjev, Z. / Naumovska, Z. / Dimovski, A. / Grozdanova, A. / Suturkova, L. et al. | 2018
-
PCN73 - BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIAPyadushkina, E. / Derkach, E.V. / Boyarskaya, T. et al. | 2018
-
PCN2 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC MELANOMA: PRELIMINARY RESULTS FROM REAL WORLDCardoso Borges, F. / Murteira, R. / Ramos, C. / Soares, P. / Ferreira, M. / Furtado, C. / Miranda, A. / Alves da Costa, F. et al. | 2018
-
PCV34 - A REVIEW ASSESSING THE INCIDENCE AND PREVALENCE OF CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTIONBiswas, A. / Agrawal, R. / Cristino, J. / Laires, P.A. et al. | 2018
-
PCV53 - IS EDOXABAN MORE COST-EFFECTIVE THAN WARFARIN IN PREVENTION OF STROKE AND DEEP VEIN THROMBOSIS?Wolfe, R.J. / Chahili, G. / Loh, F.E. et al. | 2018
-
PCV55 - ECONOMIC BURDEN OF STROKE IN GERMANY: A SYSTEMATIC REVIEWDüvel, J.A. / Damm, O. / Greiner, W. et al. | 2018
-
PCV36 - ESTIMATION OF THE INCREASED RISK ASSOCIATED WITH RECURRENT EVENTS OR POLY-VASCULAR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN THE UNITED KINGDOM FOR USE IN ECONOMIC EVALUATIONSVilla, G. / Catterick, D. / Pemberton-Ross, P. / Danese, M. et al. | 2018
-
PCV4 - NON CARDIOVASCULAR COMORBITY AND PROGNOSIS OF CONGESTIVE HEART FAILUREAizpuru, F. / Garmendia, I. / Millan, E. / Trujillo, T.G. / Librero, J. et al. | 2018
-
PCV6 - SACUBITRIL/VALSARTAN IN HEART FAILURE: PROJECTED HEALTH OUTCOMES IN PORTUGALAfonso-Silva, M. / Laires, P.A. et al. | 2018
-
PCP52 - AN ANALYTICAL FRAMEWORK FOR EFFICACY EVALUATION OF LIGHT THERAPY IN MOOD DISORDERS: THE LINKED MECHANISMS APPROACHKombeiz, O. / Schubert, T. / Vogelmann, T. et al. | 2018
-
PCP10 - PATIENT ACCESS TO NEW MEDICINES; THE CHANGING LANDSCAPERichardson, T.D. / Ling, C. et al. | 2018
-
PCN382 - QUALITY OF LIFE IN LONG-TERM CANCER SURVIVORS: IMPLICATIONS FOR FUTURE HEALTH TECHNOLOGY ASSESSMENTS IN ONCOLOGYCubi-Molla, P. / Mott, D.J. / Shah, K. / Herdman, M. / Summers, Y. / Tsuchiya, C. / Devlin, N. et al. | 2018
-
PCN379 - QUANTITATIVE COMPARISON OF THE INFLUENCE OF OPEN LABEL TRIAL DESIGN ON PATIENT REPORTED OUTCOME RESPONSES – A METASTATIC MELANOMA CASE STUDY.Knoll, S. / Pahud, D. / Tyagi, H. / Manson, S. et al. | 2018
-
PCN373 - UNDERSTANDING PATIENT PERSPECTIVES OF RENAL CELL CARCINOMA USING SOCIAL MEDIA: A QUALITATIVE ANALYSISMcDonald, L. / Merinopoulou, E. / Cox, A. / Malcolm, B. / Mehmud, F. / Ramagopalan, S. et al. | 2018
-
PCN319 - RCT NOT RWE: TWO YEAR REPORT CARD FOR THE CANCER DRUGS FUND REFORMSWalsh, S. / Liu, L.W. / Macaulay, R. et al. | 2018
-
PCN283 - IDENTIFYING THE KEY CHALLENGES AFFECTING THE REIMBURSEMENT OF CAR-T THERAPIES IN THE EU5 USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Gray, P.M. / Bhalla, S. et al. | 2018
-
PCN296 - BIG DATA ANALYSIS OF CANCER TREATMENT IN GERMANY - MAPPING OF TREATMENT LANDSCAPE BASED ON A GERMAN STATUTORY HEALTH INSURANCE (SHI) CLAIMS DATA ANALYSISMay, M. / Schellong, S. / Bruchhausen, Y. / Kretzschmar, A. / Riess, H. et al. | 2018
-
PCN288 - HAS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY DRUGS DELIVERED FASTER PATIENT ACCESS TO INNOVATIVE TREATMENTS?Chunara, F. / Foxon, G. / Craddy, P. et al. | 2018
-
PCN300 - MODERN TRENDS OF ORCHIECTOMY FOR PROSTATE CANCERHu, J. / Aprikian, A. / Dragomir, A. et al. | 2018
-
HT4 - PAN-EUROPEAN HTA – WHERE WE HAVE BEEN, WHERE WE ARE GOING?Macaulay, R. / Campbell, J. et al. | 2018
-
CN8 - COST-EFFECTIVENESS ANALYSIS OF ORAL CANCER SCREENING IN TAIWAN: A REAL WORLD DATA ANALYSISHuang, C. / Lin, C. / Wang, J. et al. | 2018
-
ND3 - META-ANALYSIS OF REAL-WORLD ADHERENCE AND PERSISTENCE OF MAINTENANCE ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS (DIMETHYL FUMARATE, FINGOLIMOD, AND TERIFLUNOMIDE) IN MULTIPLE SCLEROSISNicholas, J. / Edwards, N.C. / Edwards, R.A. / Dellarole, A. / Grosso, M. / Phillips, A.L. et al. | 2018
-
PCN341 - ESTIMATION OF UTILITIES ON SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTATIC CANCER IN KOREASuh, Y. / Ahn, J. / Park, J. et al. | 2018
-
Copyright/Subscription| 2018
-
Editorial Board| 2018
-
PHP203 - RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGALMirco, A. / Paulino, E. / Farinha, M.H. / Gil, A. / Shepherd, J. / Badia, X. et al. | 2018
-
PHP194 - THE EMA CLINICAL DATA WEBSITE: A CONCEPTUAL EXPLORATORY APPROACH TO BENCHMARK CLINICAL DEVELOPMENT INDICATORS IN MARKETING AUTHORIZATIONSLehmann, S. / Allard, R. / Boehler, Y. et al. | 2018
-
PHP195 - DO COMPANIES' MARKET ACCESS TRAINING CAPABILITIES ADDRESS THE NEEDS OF TODAY'S COMPLEX PAYER MARKETPLACE?Bailey, S. / Hewitt, C. / Craddy, P. / Foxon, G. et al. | 2018
-
PHP177 - THE USAGE OF PACKAGE CRITERIA IN DUTCH REIMBURSEMENT DECISION MAKING AND THEIR INFLUENCE ON ZIN RECOMMENDATIONSvan de Rijt, J. / Severens, J.L. / van Baal, P. / Knies, S. et al. | 2018
-
PHP165 - THE LONG-TERM CHANGE OF MEDICAL SERVICE PRICE: AN INTERNATIONAL COMPARISON OF SELECTED COUNTRIESLi, L. / Liu, B. et al. | 2018
-
PHP137 - CHANGES IN THE NUMBER OF NURSING WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Gratz, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP141 - THE PRIVATE HEALTHCARE MARKET IN BRAZIL: A REVIEW OF 18 YEARS OF PROGRESSSaggia, M.G. et al. | 2018
-
PHP136 - CHANGES IN THE NUMBER OF PHYSIOTHERAPIST WORKFORCE IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Boncz, I. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Endrei, D. et al. | 2018
-
PHP129 - CHALLENGES AND OPPORTUNITIES IN THE BIOLOGICALS-BIOSIMILARS MARKET: SUSTAINABILITY AND MARKET DIFFERENTIATIONGarcía-Goñi, M. / Cantarero, D. et al. | 2018
-
PHP114 - THE ERRATIC AND LONG ACCESS JOURNEY OF ORPHAN DRUGS FROM EUROPE TO PORTUGALFerreira, C. / Andreozzi, V. / Vandewalle, B. / Félix, J. et al. | 2018
-
PHP86 - IMPORTANCE OF CRITERIA FOR DRUG REIMBURSEMENT DECISION-MAKING FOR NON-LIFE-THREATENING DISEASESFunagoshi, M. / Murasawa, H. / Shiroiwa, T. / Saito, S. / Shimozuma, K. et al. | 2018
-
PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALYUrbinati, D. / Rova, A. / Cioni, L. et al. | 2018
-
PHP54 - DIRECTIVE 2004/18/EC: IMPLICATIONS FOR PUBLIC MEDICINE PROCUREMENT IN EUROPEZegaoui, Y. / Sogokon, P. / Morrison, S. et al. | 2018
-
PHP23 - COMPARING RISK SHARING AGREEMENTS IN CATALONIA WITH OTHERS EU COUNTRIESGuarga, L. / Fondevilla, E. / Pastor, M. / Roig, M. / Cirera, J. / Llop, C. / Alonso, E. / Obach, M. / Fontanet, M. / Gasol, M. et al. | 2018
-
PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAELWeil, C. / Chodick, G. / Shalev, V. / Demuth, D. / Petrakis, I. / Ben Baruch, O. / Tsukinovsky, S. / Yarden, A. et al. | 2018
-
PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5Annunziata, K. / Sternbach, N. / Carpinella, C.M. / Chapnick, J. / Patel, P. / McDonald, M. / McElwee, N. et al. | 2018
-
PDB111 - TREND AND FACTORS ASSOCIATED WITH PREVENTABLE HOSPITALIZATION AMONG DIABETES MELLITUS PATIENTS IN A NATIONAL HEALTH INSURANCE PROGRAMCheng, J. / Ku, H. / Huang, C. / Hsu, C. et al. | 2018
-
PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN: NATIONWIDE RETROSPECTIVE COHORT STUDYToll, A. / Eliasson, B. / Lebrec, J. / Karlsdotter, K. / Miftaraj, M. / Franzen, S. / Svensson, A. et al. | 2018
-
PDB102 - THERAPY ADJUSTMENT FOLLOWING DPP-4 INHIBITOR INITIATION IN T2DM PATIENTS WITH CREATININE CLEARANCE <50 ML/MIN: A RETROSPECTIVE COHORT STUDY USING DATA FROM UK GENERAL PRACTICESpanopoulos, D. / Barrett, B. / Busse, M. / Roman, T. / Poole, C. et al. | 2018
-
PHP345 - INNOVATIVE PAYMENT MODELS FOR BREAKTHROUGH THERAPIESHanna, E. / Dussart, C. / Auquier, P. / Toumi, M. et al. | 2018
-
PHP309 - HTA CAPACITY BUILDING - OPPORTUNITIES AND CHALLENGES AS RESULT OF HTA INSTITUTIONS RESEARCHGeorgiev, S. / Yanakieva, A. / Velikov, S. et al. | 2018
-
PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESSNeri, M. / Hampson, G. / Towse, A. et al. | 2018
-
PHP320 - ANALYSIS OF HTA PROCESS ON THE BASIS OF PHARMACOECONOMIC GUIDELINES IN CENTRAL EASTERN EUROPEAN COUNTRIESSidzhimova, D. / Benisheva, T. / Boncheva, E. / Trendafilova, P. / Kralimarkov, N. et al. | 2018
-
PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?Rémuzat, C. / François, C. / Toumi, M. et al. | 2018
-
PHP295 - REVIEW OF POSSIBLE CAUSES OF VARIATION IN NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) TECHNOLOGY APPRAISALSLing, C. / Nuabor, W. / Lyall, M. / Stevenson, A. et al. | 2018
-
PHP271 - THE GROWING IMPORTANCE OF DIGITAL CHANNELS IN FORMULARY DECISION MAKING IN THE USFiglar, H. / Arnold, M. / Wray, J. / Hoskins, N. / Fletcher-Louis, M. / Casanova, C. et al. | 2018
-
PHP278 - GUIDELINES IN GERMAN EARLY BENEFIT ASSESSMENT – WHICH GUIDELINES ARE CONSIDERED BY FEDERAL JOINT COMMITTEE FOR DETERMINING THE APPROPRIATE COMPARATOR?Scheler, E. / Stratil, A. / Roxlau, T. / Bonduelle, D. et al. | 2018
-
PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?Colasante, W. et al. | 2018
-
PHP255 - EUROPEAN "REAL-WORLD" EVIDENCE FOR DRUGS AND DEVICES: 2017 LITERATURE REVIEWEDMordin, M. / Castro, C. / Buck, P.M. / Fernandez, M.M. / Hollis, K.A. / Ritchey, M.E. et al. | 2018
-
PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS: THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCEVasilescu, L. / Faller, M. / Allou, A. et al. | 2018
-
PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATEDAlthobaiti, H.A. / Alsheikh, M.Y. / Seoane-Vazquez, E. / Lewis, J. / Brown, L.M. et al. | 2018
-
PDB85 - A 10 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) OF THE DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPP/DPPOS): CLARIFYING THE PREVIOUS CONFUSIONAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
-
PDB75 - COST-EFFECTIVENESS OF TREATING PATIENTS WITH TYPE 2 DIABETES POORLY CONTROLLED ON BASAL INSULIN WITH FIXED-RATIO COMBINATIONS OF BASAL INSULIN AND GLP-1 RECEPTOR AGONISTS IN DENMARK: IDEGLIRA VERSUS IGLARLIXIHvid, C. / Parekh, W. / Pöhlmann, J. / Hunt, B. et al. | 2018
-
PDB22 - CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS REACHING A HIGH DAILY DOSE OF IDEGLIRA SIX MONTHS AFTER INITIATION IN A REAL-WORLD SETTINGPrager, R. / Price, H. / Blüher, M. / Fernandes, J. / Møller, J.B. / Schultes, B. et al. | 2018
-
PDB25 - PRESCRIBING PATTERN IN DIABETES MELLITUS PATIENTS IN SLOVENIAJanzic, A. / Locatelli, I. et al. | 2018
-
PCV153 - ELICITING PUBLIC PREFERENCES FOR REORGANIZATION OF VASCULAR SERVICES IN THE UKWickramasekera, N. / Howard, A. / Shackley, P. et al. | 2018
-
PDB47 - THE ASSOCIATION BETWEEN RENAL FUNCTION AND HEALTHCARE COSTS IN US PATIENTS WITH TYPE 2 DIABETESLage, M.J. / Bae, J. / Mody, R. / Botros, F.T. / Wu, J. / Boye, K. et al. | 2018
-
PCV124 - HOSPITAL ADMISSIONS FOR HEART FAILURE IN ENGLAND; AN INCREASING BURDEN ON NHS RESOURCES AND THE FOCUS OF EFFECTIVE COST CONTAINMENTHickey, D.A. / Beecroft, S. et al. | 2018
-
PCV109 - ARE CARDIOVASCULAR MEDICINES IN QATAR AND LEBANON AFFORDABLE? AN ANALYSIS AND COMPARISON OF TWO DEVELOPING MIDDLE-EASTERN COUNTRIESAbdel Rida, N. / Mohamed Ibrahim, M.I. / Owusu, Y. / Babar, Z. et al. | 2018
-
PCV133 - ADHERENCE SUPPORT IN COMMUNITY PHARMACIES - THE PERCEPTION OF GERMAN PHARMACISTSLaven, A. / Nasert, S. / Katzfey, U. / Amelung, V. / Klemm, M. / Knoefler, M. / Mueller, H. / Rupprecht, C. / Unkrig, S. / Vrijens, B. et al. | 2018
-
PCV89 - CLINICAL AND ECONOMIC BURDEN OF IRON DEFICIENCY IN PATIENTS WITH CHRONIC HEART FAILUREFerreira, C. / Vandewalle, B. / Félix, J. / Gomes, S.O. et al. | 2018
-
PCN255 - CERVICAL AND BREAST CANCER IN KAZAKHSTAN BEFORE AND AFTER THE INTRODUCTION OF SCREENING: AN INTERRUPTED TIME SERIES ANALYSISSultanov, M. et al. | 2018
-
PCN272 - ANALYSIS OF PHARMACY CLAIMS FOR HIGH COST DRUGS: LENALIDOMIDE UTILISATION AND EXPENDITURE IN IRELANDMcCabe, L. / Moloney, D. / Barry, M. / Usher, C. / McCullagh, L. et al. | 2018
-
PCN269 - HEALTHCARE RESOURCE USE (HRU) ASSOCIATED WITH TREATMENT IN ADULTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) RELAPSED OR REFRACTORY (R/R) B-CELL PRECURSOR (BCP) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN EU-4 COUNTRIESZhang, X. / Zhang, L. / Gijsen, M. / Cong, Z. et al. | 2018
-
PCN214 - IBRITUMOMAB TIUXETAN RADIOLABELLED WITH YTTRIUM CHLORIDE: 4 YEARS OF USE IN THE 37 PUBLIC HOSPITALS OF PARIS AND IN FRANCEGérard, C. / Therasse, C. / Cordonnier, A. / Degrassat-Théas, A. / Paubel, P. / Fusier, I. et al. | 2018
-
PCN241 - OLAPARIB USE AND TREATMENT OUTCOMES IN SWEDISH PATIENTS TREATED DURING THE FIRST THREE YEARS FOLLOWING REGULATORY APPROVALEriksson, I. / Wettermark, B. / Bergfeldt, K. et al. | 2018
-
PCN264 - ASSESSMENT OF TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN SPAIN FOLLOWING INITIAL PLATINUM THERAPY FOR RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)Parikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Sawyer, W. / Wang, H. et al. | 2018
-
PCN198 - AN ECONOMIC SYSTEMATIC LITERATURE REVIEW (SLR) FOR ANAPLASTIC LYMPHOMA KINASE-POSITIVE (ALK+) NON-SMALL-CELL LUNG CANCER (NSCLC)Robson, R.E. / Cranmer, H. / Huang, J. / Selby, R. / Lin, H.M. / Tolley, K. et al. | 2018
-
PCN136 - A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADALakhdari, K. / Young, K.C. / Holdgate, O. / Doan, J. et al. | 2018
-
PCN133 - THE SOCIETAL IMPACT OF OBINUTUZUMAB IN THE FIRST LINE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN GERMANYHofmann, S. / Ostwald, D.A. / Himmler, S. / Launonen, A. / Dünzinger, U. / Salmen, H. et al. | 2018
-
PCN167 - IMPROVEMENT OF AN OPEN-SOURCE COST-EFFECTIVENESS MODEL BASED ON PUBLIC FEEDBACKIncerti, D. / Shafrin, J. / Lakdawalla, D.N. / Zhao, L. / Linthicum, M. / Jansen, J.P. et al. | 2018
-
PCN127 - DIRECT HEALTHCARE COSTS BY TREATMENT AMONG PATIENTS WITH MERKEL CELL CARCINOMA (MCC) IN THE UNITED STATESKearney, M. / Thokagevistk, K. / Boutmy, E. / Sherman, S. / Bharmal, M. et al. | 2018
-
PCN129 - TREATMENT COSTS AND PROGRESSION-FREE SURVIVAL OF DVD AND KRD REGIMENS SEQUENCES IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMRosim, R.P. / Julian, G. / Mendes, A. / Ricco, M. / Fioratti, C.O. / Scaccabarozzi, L. et al. | 2018
-
PCN84 - TOTAL COST OF CARE AND BUDGET IMPACT FOR PATIENTS WITH CLL TREATED WITH VENETOCLAXCho, S.K. / Samp, J.C. / Keim, H. / Masaquel, A.S. / Johnson, S.J. / Parise, H. et al. | 2018
-
PCN99 - EVALUATING THE INCREASING STRAIN OF IMMUNOTHERAPIES (PD-1/PD-L1) ON PUBLIC HEALTHCARE SYSTEMS IN T5 + USDe Cristofano, F. / Barling, H.D. / Bell, C. et al. | 2018
-
PCN117 - HEALTHCARE EXPENDITURES FOR THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA IN JAPANFukuda, H. / Ishida, H. / Sato, D. / Moriwaki, K. et al. | 2018
-
PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICOAlva, M.E. / Ortíz, M. / Flores, B. et al. | 2018
-
PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLANDHollmann, S. / Painter, C. / Hogan, A. / Morten, P. / Goyert, N. / Vieira, J. / Slowley, A. / Jousseaume, E. / El Ouagari, K. / Zhang, J. et al. | 2018
-
PCN34 - PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC – A NETWORK META-ANALYSISFrederickson, A.M. / Arndorfer, S. / Lorenzi, M. / Insinga, R. / Chandwani, S. / Burke, T. et al. | 2018
-
PCN46 - DURABLE THERAPY IN FRONTLINE CLL IMPROVES OSBaculea, S. / Horsburgh, S. / Chadda, S. / Nelson, L. / LeReun, C. et al. | 2018
-
PCN28 - A REVIEW OF THE EFFECTIVENESS OF PHOTODYNAMIC THERAPY FOR CANCERKirsanova, O. / Sukhorukikh, O. et al. | 2018
-
PCV45 - BUDGET IMPACT ANALYSIS OF ACEI AND ARBS II DRUGS IN PATIENTS WITH ARTERIAL HYPERTENSIONTolordava, G. / Yagudina, R. / Arinina, E. et al. | 2018
-
PCV23 - TIME TO TREATMENT INTENSIFICATION IN NEW STATIN USERSMachado-Duque, M. / Gaviria-Mendoza, A. / Machado-Alba, J. et al. | 2018
-
PCN376 - EXAMINING CANCER RELATED DISTRESS AMONG A GROUP OF URBAN-DWELLING VETERANS.Azizoddin, D. / Rynar, L. / Molokie, R. / Hauser, J. / Payvar, S. / Martin, J. et al. | 2018
-
PCP4 - DEVELOMENT OF A QUALITY MANAGEMENT SYSTEM FOR EUNETHTA AND THE PERMANENT EUROPEAN COLLABORATION ON HTAFathollah-Nejad, R. / Luhnen, M. / Rehrmann, M. et al. | 2018
-
PCN366 - QUALITATIVE PATIENT INTERVIEWS TO SUPPORT THE FACT HEPATOBILIARY SYMPTOM INDEX-8 AMONG PATIENTS WITH HEPATOCELLULAR CARCINOMA AND ELEVATED BASELINE ALPHA-FETOPROTEINGable, J. / Ayer, D. / Girvan, A. / Bowman, L. / Abada, P. / Ervin, C. / Evans, E. / Cella, D. et al. | 2018
-
PCP8 - BENELUXA INITIATIVE: WHY THE FIRST ATTEMPT OF JOINT ASSESSMENT FAILED?Pisarczyk, K. / Rémuzat, C. / Hajjeji, B. / Toumi, M. et al. | 2018
-
PCN361 - HEALTH ECONOMIC VALUE PROPOSITIONS FOR SUBCUTANEOUS TRASTUZUMAB AND THEIR TRANSFERABILITY TO CENTRAL-EASTERN EUROPEAN COUNTRIESInotai, A. / Ágh, T. / Karpenko, A.W. / Zemplényi, A. / Kaló, Z. et al. | 2018
-
PCP2 - IS DIGITAL TECHNOLOGY BRINGING THE ADOPTERS CLOSER TO THE DECISION-MAKERS: A COMPARATIVE ASSESSMENT ACROSS FIVE EUROPEAN MARKETS.Khan, S. / Teale, C.W. / Heupel, M. / Czira, A. et al. | 2018
-
PCN324 - EXAMINING HPV VACCINATION PRACTICES AND DIFFERENCES AMONG PROVIDERS IN VIRGINIAAlcalá, H.E. / Maxwell, G.L. / Keim-Malpass, J. / Mitchell, E. / Balkrishnan, R. et al. | 2018
-
PCN381 - REFERENCE VALUES FOR EORTC QLQ-C30 IN HODGKIN'S LYMPHOMAMierzynska, J. / Taye, M. / Pe, M. / Coens, C. / Martinelli, F. / Flechtner, H. / Meijnders, P. / Lugtenburg, P.J. / Shepherd, L. / Hertzberg, M. et al. | 2018
-
PCN314 - HEALTH-TECHNOLOGY ASSESSMENTS IN ONCOLOGY: RESULTS OF A REVIEW OF DECISIONS IN GERMANYGottschalk, F. / Mueller, S. / Wilke, T. et al. | 2018
-
PCN302 - IS THE NEW NICE APPRAISAL PROCESS FOR ONCOLOGY INDICATIONS TOO POSITIVE IN ITS ASSESSMENT OF CANCER DRUGS IN ENGLAND?Chunara, F. / Foxon, G. / Craddy, P. et al. | 2018
-
DB3 - PROOF-OF-CONCEPT STUDY OF DIGITAL SMARTPHONE APPLICATIONS TO SUPPORT SELF-MANAGEMENT OF LONG-TERM HEALTH CONDITIONSSmith, W. / Orlowski, A. / Itrakjy, A. / Porter, A. / Willis, T. et al. | 2018
-
CE4 - COST-EFFECTIVENESS ANALYSIS OF FIRST-LINE OSIMERTINIB IN PATIENTS WITH EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCERHolleman, M.S. / Al, M.J. / Uyl-de Groot, C.A. et al. | 2018
-
AD2 - A FULLY INTEGRATED CLINICAL TRIAL LIKE SYSTEM TO GUARANTEE PERSISTENCE ON PLANNED HEPATITIS C TREATMENT: EVIDENCE FROM THE REAL-WORLDGomes, I. / Figueira, A. / Sequeira, C. / Silva, S. / Machado, F. / Figueiredo, J. / Rabadão, E. / Granjeia, R. / Andreozzi, V. / Félix, J. et al. | 2018
-
PCN394 - PRICES AND COSTS OF CANCER TREATMENTS IN FRANCE: REALITIES, CHALLENGES AND PERSPECTIVESBaseilhac, E. / Dorizon, D. / Heng, C. et al. | 2018
-
PCV157 - ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE AND ATRIAL FIBRILLATION SYMPTOM BURDEN: RESULTS OF A STUDY ON ATRIAL FIBRILLATION PATIENTS IN GERMANY, SWEDEN AND SWITZERLANDWilke, T. / Bloempott, S. / Henry, M. / Mueller, S. et al. | 2018
-
PIN19 - A COST COMPARISON OF TREATING CHRONIC HEPATITIS C PATIENTS WITH SOFOSBUVIR-BASED REGIMENSRu, H. / Zhou, J. et al. | 2018
-
PIH50 - RESILIENCE AND ITS INFLUENCING FACTORS' EFFECT ON TIMELY APPEARENCE OF 2ND AND 3RD PHASE OF LACTOGENESISKarácsony, I. / Balogh, B. / Szabó, L. / Oláh, A. / Ipolyi, D. / Brantmüller, É. / Boncz, I. / Pakai, A. et al. | 2018
-
PHP356 - COMPARATIVE ANALYSIS BETWEEN OLD AND NEW ITALIAN INNOVATION RATING SYSTEMPrada, M. / Sansone, C. / Mariano, E.E. / Mantovani, M. et al. | 2018
-
PIH4 - HEALTHCARE RESOURCE USE AND COSTS ASSOCIATED WITH EXTREMELY PRETERM BIRTH IN THE NETHERLANDSHouben, E. / Siffel, C. / Overbeek, J.A. / Sarda, S.P. et al. | 2018
-
PHP360 - THE EFFECT OF EUNETHTA ASSESSMENTS ON NATIONAL HTA DECISION MAKINGChew, V.C. / Sogokon, P. / McNamara, L. / Morrison, S. et al. | 2018
-
PHP209 - FUNDING OF CLINICAL TRIALS IN UNIVERSITY HOSPITAL ENVIRONMENTZavadil, M. / Al Jamal, E.S. / Valtrová, V. et al. | 2018
-
PHP185 - BRAZIL'S ECONOMIC SITUATION AND THE EVOLUTION OF THE PRIVATE HEALTHCARE SYSTEMChabrol Haas, L. / Ranieri, A.S. / Bottino, M.C. / Clemente, V. et al. | 2018
-
PHP169 - MCDA EVIDEM REFERENCE VALUE FRAMEWORK FOR DRUG EVALUATION AND DECISION MAKING IN SPAINBadia, X. / Gil, A. / Shepherd, J. et al. | 2018
-
PHP163 - THE FRENCH HEALTH ECONOMIC RESEARCH PROGRAM(PRME): AN OVERVIEW SINCE ITS CREATION IN 2013Corthier, M. / Maillant, L. / Mézerette, B. et al. | 2018
-
PHP119 - DISRUPTION IN PATIENT ACCESS TO INNOVATIVE THERAPY IN FRANCE AFTER INTERRUPTION OF NOMINATIVE TEMPORARY AUTHORISATION FOR USEWeber, A. / Marre, C. / Leveque, D. / Toumi, M. et al. | 2018
-
PHP103 - OUT-OF-POCKET EXPENDITURE FOR PRESCRIBED AND OVER-THE-COUNTER MEDICATIONS IN GREECENaoum, P. / Kyriopoulos, I. / Karampli, E. / Athanasakis, K. / Kyriopoulos, J. et al. | 2018
-
PHP88 - CLINICAL ADDED VALUE ASSESSMENT OF ANTI-INFECTIVES FOR SYSTEMIC USE BY FRENCH TRANSPARENCY COMMITTEE IS CORRELATED WITH THE PUBLIC HEALTH BENEFITGauthier, M. / Desplanches, L. / Heurtebis, J. / Vandewalle, C. / Charoy, M. / de Sauvebeuf, C. et al. | 2018
-
PHP51 - UTILIZTION OF MONOCLONAL ANTIBODY IN CHINA: A STUDY FROM NATOINAL MARKET ACCESS VIEWLai, Y. / Bie, R. / Suo, S. / Shi, H. / Chen, S. / Ung, C.O. / Hu, H. et al. | 2018
-
PHP28 - EXPLANATIONS FOR THE DIFFERENCES BETWEEN EFFECTS ON ADHERENCE OF VALUE-BASED HEALTH INSURANCE DESIGNS: A SYSTEMATIC REVIEW AND META-ANALYSISKrack, G. et al. | 2018
-
PGI46 - PSYCHOMETRIC EVALUATION OF THE DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-CONSTIPATION (DIBSS-C)Fehnel, S. / Ervin, C. / McLeod, L. / Carson, R.T. / Reasner, D. / Hanlon, J. / Eremenco, S. / Coons, S.J. et al. | 2018
-
PHP10 - PATIENTS' INVOLVEMENT IN THE DEVELOPMENT OF TARGET PRODUCT PROFILE, PRODUCT DEVELOPMENT PLAN AND THE DESIGN OF CLINICAL TRIALSFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
-
PDB100 - STUDY ON AWARENESS REGARDING NEWER TRENDS IN DIABETES MEDICATION MANAGEMENTKarnik, S. / Janodia, M. / Jadhav, S. / Parolia, S. et al. | 2018
-
PDB105 - INCREASED BURDEN OF MULTIMORBIDITY AMONGST DIABETES PATIENTS: A MULTINATIONAL SURVEYHiggins, V. / Sullivan, E. / Harrison, O. / Piercy, J. et al. | 2018
-
PHP346 - THE EVOLUTION FROM INTEREST TO EXECUTION: AN ANALYSIS OF RECENT TRENDS IN OUTCOMES BASED CONTRACTING ACROSS THE US AND EULehmann, H. / Erickson, G. / Eslami, N. / Garfield, S. / Richardson, S. et al. | 2018
-
PHP333 - ADDRESSING THE CHALLENGE OF CHRONICITY IN A REGION OF SPAIN. TAKING STEPS TOWARDS A PARTNERSHIP BETWEEN THE HEALTH CARE ADMINISTRATION AND THE PHARMACEUTICAL INDUSTRYSánchez-Agustino, M. et al. | 2018
-
PHP331 - IS IT ENOUGH TO HAVE IT IN THE VACCINATION PROGRAMME? AN EMPIRICAL ANALYSIS OF THE FACTORS THAT AFFECT INFLUENZA VACCINATION UPTAKE IN ADULTS IN GREECEAthanasakis, K. / Kyriopoulos, I. / Kyriopoulos, J. et al. | 2018
-
PHP288 - INCLUSION OF QUANTITATIVE PREFERENCE DATA TO UNDERSTAND TREATMENT PREFERENCE IN HTA APPLICATIONS IN THE UKLewis, H.B. / Latibeaudiere, D. / Janssen, E. / Justo, N. et al. | 2018
-
PHP253 - WAYS OF IMPROVING PHARMACEUTICAL ASSISTANCE IN UKRAINE THROUGH THE DEVELOPMENT OF PHARMACEUTIST PROTOCOLSLishchyshyna, O. / Shilkina, O. et al. | 2018
-
PHP212 - A DECADE OF PUBLIC-PRIVATE PARTNERSHIPS (PDPS) IN BRAZIL: AN EXPLORATORY ANALYSIS OF PROGRESS AND CHALLENGESMusleh, E. / Saggia, M.G. et al. | 2018
-
PDB91 - EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOMBodaghi, C. / Benque, E. / Troubat, A. et al. | 2018
-
PDB80 - RE-ANALYSIS OF THE DIABETES PREVENTION PROGRAM 3 YEAR COST-EFFECTIVENESS ANALYSIS (CEA) USING IDENTICAL DATA BUT PROPER METHODS QUESTIONS ITS CONCLUSIONSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
-
PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCERMuzio, V. / Gonzalez, O. / Garcia, D. / Flores, B. / Alcantara, J.L. / Figueroa, A. / Lemus, F. et al. | 2018
-
PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICECarrasco Perez, M. / Male, N. / Serra Burriel, M. / Pfarr, E. / Kansal, A. et al. | 2018
-
PDB43 - THE COSTS AND RESULTS OF INCRETINS'AND SGLT-2I DIABETES THERAPY IN BULGARIAMitkova, Z. / Valov, V. / Mitov, K. / Manova, M. / Savova, A. / Kamusheva, M. / Tcharaktchiev, D. / Angelov, Z. / Angelova, G. / Petrova, G. et al. | 2018
-
PDB45 - COSTS OF PREVENTION, MONITORING AND TREATMENT OF IODINE DEFICIENCY DISORDERS IN GERMANYSchaffner, M. / Rochau, U. / Mühlberger, N. / Conrads-Frank, A. / Sroczynski, G. / Vukićević, D. / Koukkou, E. / Voelzke, H. / Thuesen, B.H. / Qerimi, V. et al. | 2018
-
PDB50 - COST OF HYPOGLYCAEMIA IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. et al. | 2018
-
PDB13 - SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS OF SGLT-2 INHIBITORS AND METFORMIN AS ADD-ON TO INSULIN FOR THE TREATMENT OF TYPE 1 DIABETESLangford, B. / Evans, M. / Haskins-Coulter, T. / O'Connor, M. / Eddowes, L.A. / Edmonds, C. / Tank, A. et al. | 2018
-
PCV115 - QUALITY OF INR CONTROL AND SWITCHING TO DOAC BETWEEN WOMEN AND MEN WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN. A POPULATION-BASED, REAL-WORLD STUDY.Garcia-Sempere, A. / Hurtado, I. / Bejarano, D. / Rodriguez-Bernal, C. / Santaana, Y. / Peiro, S. / Sanfelix, G. et al. | 2018
-
PDB9 - ASSOCIATION BETWEEN CLASS OF ANTIDIABETIC DRUGS AND INCIDENCE OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELITUS: A PROPORTIONAL HAZARD ANALYSIS USING DEEP LEARNING FOR RISK ADJUSTMENTYamada, T. / I.T.O., K. / Takeshima, T. / Iwasaki, K. et al. | 2018
-
PCV147 - A TARGETED LITERATURE REVIEW OF HEALTH STATE UTILITIES IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)Dimri, S. / Agrawal, R. / Cristino, J. / Laires, P.A. et al. | 2018
-
PCV84 - COST-EFFECTIVENESS ANALYSIS OF APIXABAN VERSUS EDOXABAN FOR STROKE PREVENTION IN NON-VALVULAR ATRIAL FIBRILLATION SPANISH PATIENTSde Andrés-Nogales, F. / Oyagüez, I. / Suarez, C. / Lopez-Sendon, J.L. / Gonzalez-Juanatey, J.R. / Suarez, J. / Polanco, C. et al. | 2018
-
PCV68 - POTENTIAL SAVINGS IN HIGHEST PRESCRIBING REGIONS FOR DIRECT-ACTING ORAL ANTICOAGULANTS IN ENGLANDOrlowski, A. / Slater, R. / Smith, W. / Ashton, R. / Dewar, T. et al. | 2018
-
PCN238 - TIME TO APPROVAL USING ACCELERATED MARKETING AUTHORIZATION PATHWAYS: A STUDY OF FIVE DEVELOPED COUNTRIESBerdunov, V. / Mesana, L. / Hancock-Howard, R. / Syed, I.A. et al. | 2018
-
PCV71 - COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN FOR THE TREATMENT OF SYMPTOMATIC CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PORTUGALAlarcão, J. / Ascenção, R. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
-
PCN253 - DID THE EUROPEAN FINANCIAL CRISIS HAVE AN IMPACT ON ECONOMIC DECISION-MAKING IN HEALTH TECHNOLOGY ASSESSMENTS?Gizaw, N. / Farinella, M. / Inumerable, R.V. / Rubinstein, J. / Ho, Y. et al. | 2018
-
PCN251 - DESCRIPTIVE ANALYSIS OF THE USE OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKAEMIA IN EUROPE, A REAL-WORLD PERSPECTIVEMartinez de Pinillos, A. / Nasuti, P. / Anger, C. / Ricote, I. et al. | 2018
-
PCN203 - HEALTHCARE RESOURCE USE IN PATIENTS WITH END-STAGE ADVANCED CUTANEOUS T-CELL LYMPHOMA (CTCL): RESULTS OF SEVEN SEMI-STRUCTURED INTERVIEWS ACROSS LEADING UK CENTRESPodkonjak, T. / Ovcinnikova, O. / Cranmer, H. / Benson, E.M. / Hatswell, A.J. / Field, F. et al. | 2018
-
PCN158 - THE ADDED VALUE OF PERSONALIZED FOLLOW-UP FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTSBakker, L.J. / Redekop, K. / Aarts, J.E. et al. | 2018
-
PCN205 - OUTCOMES OF DECISION AIDS USED IN ONCOLOGY: A SYSTEMATIC REVIEWCovvey, J.R. / Kamal, K.M. / Dhumal, T. / Mehta, Z. / Zacker, C. et al. | 2018
-
PCN164 - THE APPLICATION OF A RESPONSE-BASED MODELLING APPROACH WITH A LANDMARK POINT: IMPLICATIONS AND CHALLENGES FOR THE ECONOMIC EVALUATION OF NIVOLUMAB FOR ADVANCED/METASTATIC UROTHELIAL CARCINOMA IN THE UKGreen, W. / Shore, J. / Schoenherr, N. / Wickstead, R.M. / Tyas, D. et al. | 2018
-
PCN165 - COST-EFFECTIVENESS OF SORAFENIB FOR METASTATIC RENAL CELL CARCINOMA: A SYSTEMATIC REVIEWTaheri, S. / Motevalli, M.H. / Peiravian, F. / Yousefi, N. et al. | 2018
-
PCN126 - DIRECT COST STUDY OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVEDuteil, E. / Lafon, T. / Blein, C. / Affinito, S. / Duco, J. / Oprea, C. / Vieira dos santos, C. et al. | 2018
-
PCN112 - BURDEN AND COSTS OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN PORTUGALPaquete, A.T. / Silva Miguel, L. / Costa, J. / Alarcão, J. / Fiorentino, F. / Guerreiro, R. / Borges, M. et al. | 2018
-
PCN85 - SAVING HEALTHCARE AND SOCIETAL COSTS BY CHANGING THE ROUTE OF ADMINISTRATION OF ONCOLOGY DRUGSFranken, M.G. / Kanters, T.A. / Coenen, J.L. / de Jong, P. / Koene, H.R. / Lugtenburg, P.J. / Jager, A. / Uyl-de Groot, C.A. et al. | 2018
-
PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A SYSTEMATIC ASSESSMENT OF TRIAL DATAWang, S. / Varol, N. / Waser, N. / Thompson, J.C. / Penrod, J.R. / Yuan, Y. / Korytowsky, B. / Hertel, N. / Goring, S.M. et al. | 2018
-
PCN91 - PHARMACOECONOMIC EVALUATION OF ENZALUTAMIDE FOR THE TREATMENT OF POST-CHEMOTHERAPY PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN RUSSIAAvxentyev, N.A. / Derkach, E.V. / Makarov, A.S. et al. | 2018
-
PCN22 - MARKETING AUTHORISATION PRACTICE OF THE EUROPEAN MEDICINES AGENCY (EMA) IN ONCOLOGICAL INDICATIONSKordecka, A. / Walkiewicz-Żarek, E. / Łapa, J. / Sadowska, E. / Kordecki, M. et al. | 2018
-
PCN189 - ANALYSIS COST / UTILITY OF THE THERAPEUTIC THERAPY TREATMENT OF LUNG CANCER IN A UNIVERSITY HOSPITAL OF SPAINReyes-Santias, F. / Cordova-Arevalo, O. et al. | 2018
-
PCN18 - TREATMENT OF POST-MENOPAUSAL ADVANCED BREAST CANCER: NETWORK META-ANALYSIS USING SECOND-ORDER FRACTIONAL POLYNOMIALS MODELSHarvey, R.C. et al. | 2018
-
PCN4 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCERMurteira, R. / Ramos, C. / Cardoso Borges, F. / Ferreira, M.M. / Miranda, A. / Alves da Costa, F. et al. | 2018
-
PCN9 - BRAIN TUMOR RESECTION SURGERY IN PEDIATRIC PATIENTS; RETROSPECTIVE EPIDEMIOLOGICAL STUDY USING JAPANESE ADMINISTRATIVE DATABASEShinjo, D. / Matsumoto, K. / Terashima, K. / Takimoto, T. / Noguchi, T. / Fushimi, K. et al. | 2018
-
PCN1 - REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SMALL-CELL LUNG CANCER (SCLC) TREATMENTS: A SYSTEMATIC LITERATURE REVIEW (SLR)Povsic, M. / Enstone, A. / Wyn, R. / Kornalska, K. / Penrod, J.R. / Yuan, Y. et al. | 2018
-
ND1 - AMBULATORY FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY (DMD): THE CHARACTERISTIC TRAJECTORY AND VARIATION ACROSS INDIVIDUALSSignorovitch, J. / Muntoni, F. / Sajeev, G. / Yao, Z. / Ward, S.J. / Abrams, K.R. et al. | 2018
-
PCN6 - SYSTEMATIC LITERATURE REVIEW OF EFFICACY & SAFETY DATA FOR THE TREATMENT OF PREVIOUSLY UNTREATED, ADVANCED OR METASTATIC RENAL CELL CARCINOMABregman, C. / Supiot, R. / Pacou, M. / Doan, J. / Dale, P. / Malcolm, B. et al. | 2018
-
PCN15 - INVESTIGATION OF THE ASSOCIATION BETWEEN INCIDENT METFORMIN EXPOSURE AND NON-SMALL CELL LUNG CANCER DIAGNOSIS AMONG DIABETIC PATIENTSRuban, C. / Blanchette, C.M. / Howden, R. / Kowalkowski, M. / Marino, J. / Saunders, W.B. et al. | 2018
-
PCN147 - COST-EFFECTIVENESS SIMULATION AND ANALYSIS OF COLORECTAL CANCER SCREENING IN SHANGHAI POPULATION, CHINA: COMPARISON BETWEEN URBAN AND RURAL RESIDENTSDou, G. / Li, X. / Ying, X. et al. | 2018
-
PCN12 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN WESTERN EUROPEDaSilva, C. / Karki, C. / Wriede, V. et al. | 2018
-
PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT: A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPYKuranz, S. et al. | 2018
-
HT5 - FINDINGS FROM THE FIRST FIVE YEARS OF THE UK NICE HST PROGRAMCockerill, K. / Gaebler, J.A. et al. | 2018
-
MD3 - FROM DRUG-DELIVERY DEVICE TO DISEASE MANAGEMENT TOOL: A STUDY OF PATIENT PREFERENCES FOR ENHANCED FEATURES IN NEXT GENERATION SELF-INJECTION DEVICESBoeri, M. / Szegvari, B. / Hauber, B. / Mange, B. / Mountian, I. / Schiff, M. / Maniadakis, N. et al. | 2018
-
PCV57 - HEALTH INSURANCE COST OF HYPERTENSIVE HEART DISEASE IN HUNGARY: A NATIONWIDE COST OF ILLNESS STUDYGazsó, T. / Boncz, I. / Sebestyén, A. / Gratz, B. / Endrei, D. et al. | 2018
-
PCV37 - IDENTIFICATION OF FACTORS AFFECTING READMISSIONS IN HEART FAILURE PATIENTSAkkineni, S.S. / Mohammed, O. / Kunhikatta, V. / Kumar, J.P. / Devasia, T. et al. | 2018
-
PCP3 - ADAPTIVE PATHWAYS 2020: WHAT'S ON THE HORIZON IN THE NEXT 2-3 YEARS?Rejon-Parrilla, J.C. / Bouvy, J. et al. | 2018
-
PCP23 - DOES THE EUROPEAN UNION (EU) NEED EUROPEAN HTA OR EUROPEAN PROCUREMENT?Toumi, M. / Rémuzat, C. / Auquier, P. / Borrisov, B. / Espín, J. / Postma, M.J. / Ruggeri, M. / Wilk, N. / Simoens, S. et al. | 2018
-
PCP45 - THE ROLE OF CROSSOVER AND TREATMENT SWITCHING IN INDIRECT TREATMENT COMPARSON IN IMMUNO-ONCOLOGYIshak, K.J. / Muszbek, N. / Altincatal, A. / Sarri, G. / Schlichting, M. / Zhou, J. et al. | 2018